Stockwinners Market Radar for February 28, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:35 EST Aquestive Therapeutics presents positive topline phase 1 results for AQST-109 - Aquestive Therapeutics presented a late breaking poster recapping positive topline data from a Phase 1 pharmacokinetic study of AQST-109 epinephrine oral film at the American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting, which was held from February 25-28 in Phoenix, Arizona. "This poster presentation provides the opportunity to share our first-in-human data for AQST-109 to the international allergy community," stated John Oppenheimer, M.D., FAAAAI, Clinical Professor of Medicine at UMDNJ Rutgers, Pulmonary and Allergy Associates NJ. "Dosing with AQST-109 resulted in PK and PD responses that were within the expected therapeutic range. This is the first time it has been demonstrated that epinephrine can achieve therapeutic blood concentrations following sublingual administration. AQST-109 shows promise as a viable alternative to injection for the management of anaphylaxis. I look forward to further evaluation of this investigational medicine."

20:30 EST Cathie Wood's ARK Investment bought 43K shares of Blade Air Mobility today

19:01 EST Cavco Industries acquires manufacturing facility in North Carolina - Cavco Industries "announced that an agreement has been signed to acquire a 184,000 square-foot manufacturing facility in Hamlet, North Carolina, which will be modified to produce homes built under the standards of the U.S. Department of Housing and Urban Development. The seller, Volumetric Building Companies, currently produces multi-family residential and commercial projects in the facility and intends to move that production closer to their markets in the Northeast."

18:04 EST Workday sees FY23 subscription revenue at $5.53B-$5.55B, up 22% y/y - CFO Barbara Larson says: "Our exceptional fourth quarter and full-year fiscal 2022 results reflect the broad-based momentum that we see across the business. Given the strength in our fourth quarter and our optimism that the environment will remain robust for finance and HR transformation initiatives, we are raising our guidance for fiscal 2023 subscription revenue to be in a range of $5.530 billion to $5.550 billion, representing year-over-year growth of 22%. We are also raising our fiscal 2023 non-GAAP operating margin guidance to 18.5%. Our market position has never been stronger, and investing to support long-term growth remains our priority."

17:52 EST L3Harris Technologies awarded $3.69B Navy contract - L3Harris Technologies was awarded an estimated cumulative $3.69B indefinite-delivery/indefinite-quantity, firm-fixed-price contract for procurement of Portable Radios and Ancillary Parts Program. The procurement includes fielding of handheld, manpack, fixed mount/vehicular and base-station radios that fulfill Office of the Chief of Naval Operations-approved legacy tactical, portable radio requirements, including high-frequency, very-high frequency, ultra-high frequency, line-of-sight and satellite communications requirements for secure/nonsecure voice and data communications, DAMA-IW and emergency communications for ships. Work will be performed at L3Harris Corporate office in Rochester, New York. As an indefinite-delivery/indefinite-quantity contract, no funding will be placed on contract and obligated at the time of award. Operations and maintenance funding via the Army, Navy, Air Force and Marine Corps will be funded on each delivery order. The period of performance will consist of a five-year ordering period; work could continue through February 2027. Funds will expire at the end of the current fiscal year. This sole source contract was not competitively procured in accordance with 10 U.S. Code 2304- Only One Responsible Source. The Naval Information Warfare Systems Command, San Diego, California, is the contracting activity.

17:39 EST Progyny reports Q4 EPS 15c, consensus 4c - Reports Q4 revenue $127.55M, consensus $136.08M. "While member utilization for October and November was strong and consistent with our expectations, the emergence and rapid spread of the COVID-19 Omicron variant affected activity in December and January," said Pete Anevski, CEO of Progyny. "As the effects of the Omicron wave began to subside, we saw our members return to care at more typical levels starting in February, demonstrating yet again the continued resilience of fertility patients in their pursuit of care, even against the backdrop of a global pandemic."

17:09 EST Clover Health appoints Conrad Wai as chief technology officer - Clover Health announced the appointment of Conrad Wai as chief technology officer, or CTO, to drive development and growth of Clover's flagship technology platform, the Clover Assistant. Wai will report to Andrew Toy, who will maintain oversight of the company's technology strategy in his role as president.

17:05 EST Seacoast Banking hires James Stallings as chief credit officer - Seacoast Banking announced that it has hired James Stallings, a banking and credit risk leader with nearly 25 years of experience, as executive vice president and chief credit officer. Stallings succeeds Richard Raiford, who recently retired.

17:03 EST AMC Theatres names Dan Ellis as COO, Eliot Hamlisch as CMO - AMC :announced a long-planned succession within its executive team. It has promoted Dan Ellis, currently the Senior Vice President, Development and International, as the new Executive Vice President, Chief Operations & Development Officer. In addition, it has selected Eliot Hamlisch as Executive Vice President and Chief Marketing Officer, after an extensive national search. Given the greatly expanded and time-consuming new role for Ellis, international duties, which previously reported to Ellis, will shift instead to be supervised by AMC EVP & CFO Sean Goodman. Ellis succeeds John McDonald, who is retiring as the head of U.S. Operations after a 47-year movie theatre career, all with AMC. Hamlisch takes over marketing leadership from Stephen Colanero, who is retiring after 12 distinguished and innovation-filled years as the CMO at AMC."

17:00 EST Design Therapeutics announces FDA clearance for DT-216 IND - Design Therapeutics announced that its Investigational New Drug Application, or IND, for its lead candidate, DT-216, for the treatment of Friedreich ataxia, or FA, was cleared by the FDA. The company is preparing to initiate a Phase 1 clinical trial of DT-216 to assess the safety, tolerability, pharmacokinetics, and frataxin levels in patients with FA. Study enrollment is expected to begin in the coming weeks.

16:54 EST Washington REIT promotes Susan Lilly Gerock to Chief Information Officer - "Having increased its emphasis on data and technology initiatives as a focused apartment owner and operator,"WashREIT announced that Susan Lilly Gerock, Chief Information Officer, has been promoted to Senior Vice President. Gerock joined WashREIT in April 2016 as Vice President, Information Technology and Chief Information Officer and has over 25 years of experience in various technology roles spanning real estate, consulting, application services, and manufacturing organizations. Her specialties include project and change management, cybersecurity, and ERP selection and implementation. Gerock is leading the transformation of WashREIT's infrastructure as the Company expands into Southeast markets and focuses on elevating residents' expectations for value-driven living. In addition to transforming the Company's infrastructure, she is responsible for the leadership, integrative management, and direction for Company information systems including corporate-wide planning, budgeting for information technologies and coordination and integration of all company information.

16:41 EST SmartSky Networks filed a patent infringement against Gogo - SmartSky Networks filed a patent infringement lawsuit in U.S. Federal District Court in Delaware that could block Gogo Business Aviation (GOGO) from selling its "Gogo 5G" inflight Internet service and related hardware, which includes any required components, AVANCE L5, Gogo X3, and antennas. SmartSky also filed a motion for preliminary injunction, asking the court to immediately stop Gogo from making, using, and selling Gogo 5G while the infringement case proceeds. The complaint argues that after years of desperately trying to acquire more licensed spectrum, Gogo abruptly changed course and copied SmartSky's patented approach of using unlicensed spectrum to launch its new Gogo 5G inflight Internet service.

16:40 EST Phillips 66 adds 2050 target to greenhouse gas emissions reduction plans - Phillips 66 announced that it intends to reduce the greenhouse gas emissions intensity from its operations companywide 50% by 2050. The new target builds upon the company's previously announced Scope 1 and 2 GHG emissions reduction targets. "We are committed to being part of the solution and helping the world address climate change," said Phillips 66 Chairman and CEO Greg Garland. "Our 2050 target further reflects our drive to create shareholder value and ensure Phillips 66 participates in the energy transition." Phillips 66 introduced 2030 targets last year, signaling its commitment to taking action and reducing the carbon intensity of its operations. Both sets of targets are compared to 2019 levels. "We support the ambitions of the Paris Agreement and are increasing our commitment with the 2050 target," Garland said. "We will continue to prioritize our resources to drive innovation and do our part. The company's investments to meet its targets will be consistent with its disciplined approach to capital allocation." The company's 2022 capital program of $1.9 billion includes $916 million for growth capital, of which 45% supports lower-carbon opportunities.

16:38 EST GrafTech CEO David Rintoul announces intent to retire - GrafTech International announced that David J. Rintoul has informed the Company of his intent to retire as Chief Executive Officer and President and as a member of the Board of Directors of the Company, effective as of the end of June 2022, or such later time as a successor has been appointed to ensure a smooth transition. "On behalf of the Board, I would like to thank David for his dedicated service to GrafTech since the Company went public in 2018," said Denis Turcotte, Chair of GrafTech's Board. "We are grateful to David for his strong leadership on behalf of all stakeholders and wish him all the best in his upcoming retirement." The Board has authorized the Nominating and Corporate Governance Committee, which is working with a leading executive search firm, to conduct a global search and assist in considering both internal and external candidates. The Committee will make recommendations to the Board with the Board making the final decision on a successor.

16:38 EST Acadia Pharmaceuticals reports Q4 EPS (27c), consensus (24c) - Reports Q4 revenue $130.8M, consensus $135.6M. "Acadia delivered strong fourth quarter and full year results with an increase in net sales of 10 percent year-over-year, driven by growth in both NUPLAZID prescriptions and market share," said Steve Davis, Chief Executive Officer. "We recently resubmitted our sNDA for pimavanserin for Alzheimer's disease psychosis to the FDA. In addition, this year we plan to submit an NDA for trofinetide for the treatment of Rett syndrome, complete enrollment in our pivotal ADVANCE-2 study for pimavanserin for the negative symptoms of schizophrenia, and deliver results from two Phase 2 studies for ACP-044 in postoperative and osteoarthritis pain."

16:36 EST Revance expects cash to fund operations into 2023 - Revance expects 2022 GAAP operating expenses to be $375M-$400M and non-GAAP operating expenses, which exclude costs of revenue, depreciation and amortization and stock-based compensation to be $260 million to $280 million. Revance expects 2022 non-GAAP research and development expense to be $100 million to $110 million. With the current cash, cash equivalents and short-term investments, management projects that the company is funded into 2023, excluding the proceeds of any financing transactions.

16:35 EST Rand Capital raises quarterly dividend 50% to 15c per share - Rand Capital announced that its Board of Directors declared its regular quarterly cash dividend distribution of $0.15 per share. This quarterly dividend represents a $0.05 per share increase from the previous regular quarterly dividends in 2021. The cash dividend will be distributed on or about March 28, 2022, to shareholders of record as of March 14, 2022. "This dividend increase reflects the continued transformation of our portfolio to contain more income producing investments and takes into account our conservative expectations of the income from our current portfolio and our initial tax-based expense projections," commented, Daniel P. Penberthy, President and Chief Executive Officer of Rand. "We have expectations of continued growth and remain committed to delivering value to our shareholders."

16:32 EST West Pharmaceutical names Eric Green as Chair of Board - West Pharmaceutical announced Eric M. Green, President and CEO, will assume the additional responsibility of Chair of the company's Board of Directors, effective as of West's next Annual Shareholders' Meeting, which is expected to be May 24, 2022. Mr. Green will succeed Patrick Zenner, who will retire from the company's Board at that time.

16:28 EST Aris Water Solutions sees FY22 adjusted EBITDA $150M-$160M - Aris anticipates continued rapid growth in 2022 due to accelerating activity on the Company's dedicated acreage and increasing adoption of recycling as customers recognize our reliability and sustainability benefits. For the year of 2022, the Company projects Adjusted EBITDA of $150.0-$160.0 million, growing approximately 30% versus 2021, and capital expenditures of $80.0-$90.0 million. The Company projects approximately $50.0-$60.0 million of capital expenditures for the first half of the 2022 to support anticipated production increases in the second half of 2022. For the first quarter of 2022, the Company expects Adjusted EBITDA of $32.0-$34.0 million.

16:25 EST AbbVie provides update on SKYRIZI in Crohn's Disease treatment - AbbVie "announced that the FDA has extended its review period for SKYRIZI(R) for the treatment of moderate to severe Crohn's disease in patients 16 years and older. The FDA has extended the Prescription Drug User Fee Act action date by three months to review additional data submitted by AbbVie, including information about the on-body injector, for this new proposed indication. Currently approved indications for SKYRIZI are not affected by this extension. SKYRIZI was approved in the U.S. in 2019 to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Earlier this year, the FDA approved SKYRIZI to treat active psoriatic arthritis in adults."

16:22 EST SailPoint jumps 9% to $45.06 after Q4 revenue beat

16:20 EST Penske Automotive acquires TEAM Truck Centres - Penske Automotive "announced that it has acquired TEAM Truck Centres, a retailer of medium and heavy-duty Freightliner and Western Star commercial trucks, located in Ontario, Canada. The acquisition is expected to generate approximately $150M in annualized revenue, building further scale within the Company's wholly-owned Premier Truck Group subsidiary."

16:16 EST Lucid updating 2022 production outlook for Lucid Air to a range of 12-14K units - "We are at the precipice of a global transition toward electric vehicles, and Lucid, with our leading technology and design, is at the forefront of one of the most significant transformations in mobility in generations. As we continue to put our cars into customers' hands, we are more confident than ever that we're building a quality foundation on which we can scale this business. We're thrilled to have been awarded the 2022 MotorTrend Car of the Year, and customers are telling us just how much they love this car. Lucid Air's 500-plus miles of range has been independently validated under real-world conditions, even at a steady 70mph, replacing range anxiety with range confidence. We believe that the unique fusion of a dynamic driving experience, interior space and comfort, range, fast charging and performance is simply unparalleled. Additionally, our software over-the-air updates continue to enable an ever-improving ownership experience. Looking ahead, we're updating our outlook for 2022 production to a range of 12,000 to 14,000 vehicles. This reflects the extraordinary supply chain and logistics challenges we've encountered and our unrelenting focus on delivering the highest-quality products. We remain confident in our ability to capture the tremendous opportunities ahead given our technology leadership and strong demand for our cars," said Peter Rawlinson, Lucid's CEO and CTO.

16:15 EST GoodRx announces $250M share repurchase program - GoodRx Holdings announced that its Board of Directors approved a share repurchase program with authorization to purchase up to $250 million of its Class A Common Stock, effective immediately. "This share repurchase program demonstrates the confidence we have in the future of our business and our commitment to creating long-term, sustainable value for our shareholders," said Doug Hirsch, co-CEO and co-founder of GoodRx. "We believe the investments we are making in our platform, product, user experience, and brand, in addition to a share repurchase program, will allow us to unlock more of the long-term opportunity we see ahead."

16:14 EST Gulfport Energy sees FY22 capital investment roughly $360M - Sees FY22 net production roughly 1 Bcfe/d. "Our 2022 development program is centered around more consistent drilling operations in the Utica, allowing for increased operational efficiencies and opportunities for incremental cost reductions. We anticipate this level of activity will result in production growth of more than 5% in 2023 and modest growth through 2025. We will continue to prioritize the return of capital to shareholders and, now that we have reached our target leverage ratio, look forward to beginning to execute our previously announced stock repurchase program, which we believe holds significant value at recent trading levels."

16:10 EST Zoom Video announces $1B stock repurchase plan - Zoom's board of directors has authorized a stock repurchase program of up to $1B of Zoom's outstanding Class A common stock. The program will expire in February 2024.

16:06 EST Intellia Therapeutics, Regeneron announce data from phase 1 study of NTLA-2001 - Intellia Therapeutics (NTLA) and Regeneron (REGN) "announced positive interim data from an ongoing Phase 1 clinical study of their lead in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. The interim data released today include 15 hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients treated across four single-ascending dose cohorts. Single doses of 0.1 mg/kg, 0.3 mg/kg, 0.7 mg/kg, and 1.0 mg/kg of NTLA-2001 were administered via intravenous infusion and changes from baseline values of serum transthyretin (TTR) protein were measured for each patient. Treatment with NTLA-2001 led to dose-dependent reductions in serum TTR and achieved maximal reductions by day 28, with mean reductions of 52%, 87%, and 86% among the three patients each in the 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg dose groups, respectively, and 93% among the six patients in the 1.0 mg/kg dose group. Mean serum TTR reduction remained durable through the observation period, with patient follow-up ranging from two to 12 months. Additionally, the serum TTR reduction observed was consistent across all patients receiving doses at or greater than 0.3 mg/kg. At the 1.0 mg/kg dose level, all six patients achieved greater than 80% reduction and four of six patients achieved greater than 90% reduction by day 28. Further, the reduction in serum TTR observed at day 28 was sustained through the last measured timepoint for each of the six patients, which ranged from two to six months."

16:04 EST Albertsons commences review of strategic alternatives - The Board of Directors of Albertsons Companies announced that it has commenced a Board-led review of potential strategic alternatives aimed at enhancing Albertsons' growth and maximizing shareholder value. The review will include an assessment of various balance sheet optimization and capital return strategies, potential strategic or financial transactions and development of other strategic initiatives to complement Albertsons' existing businesses, as well as responding to inquiries. The Company has retained Goldman Sachs and Credit Suisse to serve as financial advisors to assist in this review. "The Board believes the continuing strength of our business and the scale of our portfolio of assets warrants a deep and considered review of all possible paths towards maximizing value creation," said Chan Galbato, Co-Chair of the Board of Directors. "Albertsons operates more than 2,270 stores across 34 states with growing digital and omnichannel capabilities, along with a vast dedicated manufacturing and distribution infrastructure, which have become integral to the fabric of communities across the U.S. The Board believes that this review, coupled with an ongoing focus on accelerating our transformation strategy, will create enhanced value for all our stakeholders including our customers, associates, and investors." The Board has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic alternatives at this time. There can be no assurance that the review will result in any transaction or other strategic change or outcome. The Company does not intend to comment further until it determines that further disclosure is appropriate or necessary.

16:03 EST Luminar announces key business milestones for 2022 - Targeted Key Business Milestones to Achieve by Year-End 2022: Iris Industrialization for Series Production: achieve series production readiness for Iris lidar and core software. Software: achieve the beta release of Sentinel, advancing Proactive Safety(TM) and Highway Autonomy capabilities. Commercial Programs: grow commercial success with existing major commercial program wins. Additionally, Luminar is targeting to achieve 40% additional major commercial wins. Forward-Looking Order Book: achieve forward-looking order book growth of at least 40% YoY in 2022.

15:27 EST Target to add more than 250 Ulta Beauty at Target locations in 2022 - Target (TGT) stated in a post to its corporate website: "When Ulta Beauty at Target launched last August, we knew the dynamic partnership was something special. And our super fans and new guests alike agree. They can't get enough of the incredible prestige assortment and one-of-a-kind shopping experience - not to mention the joy of two amazing rewards programs. The beauty destination continues to perform, driving increased traffic, awareness and loyalty. And today, we're excited to share there's even more to love as we plan to add more than 250 Ulta Beauty at Target locations in 2022, building toward 800 total." Reference Link

13:58 EST Equinor to start exiting from joint ventures in Russia - In a regulatory filing earlier this morning, Equinor disclosed that its board of directors has decided to stop new investments into Russia, and to start the process of exiting Equinor's Russian joint ventures. In addition, early this week Equinor will present a commitment to contribute funding to the humanitarian effort in the region, the company stated. "We are all deeply troubled by the invasion of Ukraine, which represents a terrible setback for the world, and we are thinking of all those who are suffering because of the military action. In the current situation, we regard our position as untenable. We will now stop new investments into our Russian business, and we will start the process of exiting our joint ventures in a manner that is consistent with our values. Our top priority in this difficult situation is the safety and security of our people. We have employees from both Ukraine and Russia, and we are proud of how our people from different backgrounds and nationalities collaborate - with mutual respect, as one team in Equinor," says Anders Opedal, President and CEO of Equinor. "Equinor has been in Russia for over 30 years and entered a cooperation agreement with Rosneft in 2012... Equinor has operated in compliance with Norwegian, European Union and United States' sanctions. Equinor maintains close contact with the authorities in Norway, the European Union, the United States, and other countries, and will continue to comply with any new sanctions relevant to our operations. At the end of 2021 Equinor had $1.2 billion in non-current assets in Russia. We expect that the decision to start the process of exiting Joint Ventures in Russia will impact the book value of Equinor's Russian assets and lead to impairments," the company stated.

13:19 EST Linde boosts quarterly dividend 10% to $1.17 per share - Linde announced that its board has declared a quarterly dividend of $1.17 per share, reflecting a 10% increase over the previous quarter's dividend. The dividend is payable on March 25, to shareholders of record on March 11. "In 2021, Linde again generated record cash flow," said incoming Chief Executive Officer, Sanjiv Lamba. "Our capital allocation priorities are to maintain a strong balance sheet, invest in high-quality growth opportunities and continue our track record of paying and annually increasing the dividend. Any surplus cash will be used to reward shareholders through a share repurchase program."

13:07 EST Tutor Perini subsidiary awarded C$341M contract by FortisBC Energy - Tutor Perini announced that its subsidiary, Frontier-Kemper Constructors, has been awarded a contract valued at approximately C$341M, or $267M, by FortisBC Energy for the tunnel component of the Eagle Mountain - Woodfibre Gas Pipeline project. The project consists of using two tunnel boring machines to bore an approximately nine-kilometer tunnel between the town of Squamish, British Columbia, Canada and the Woodfibre LNG industrial site, located southwest of downtown Squamish. Pre-construction activities, including design, procurement and construction planning, are expected to commence in March 2022 with construction anticipated to begin in early 2023. Substantial completion is anticipated in 2025. The contract value will be included in the company's first-quarter 2022 backlog, Tutor Perini said.

13:03 EST iRhythm announces results of KP-Rhythm2 study published in journal - iRhythm Technologies announced that the results of the KP-Rhythm2 study, titled "Diagnostic yield, outcomes and resource utilization with different ambulatory electrocardiographic monitoring strategies," were published in the American Journal of Cardiology, or AJC. "While earlier peer-reviewed studies have found Zio XT to be better than Holter and event monitors in the detection of arrhythmias, the KP-Rhythm2 study, led by Kaiser Permanente and supported by a research grant from iRhythm Technologies, Inc., is the first study to address specifically Zio XT patch vs. a 30-day event monitor yielding similar diagnostic yield for atrial fibrillation/ atrial flutter greater than or equal to 30 seconds in a general population of adults without known prior AF/AFL," the company said. "It's been demonstrated that Holter monitors often result in repeat testing, longer time to diagnosis, increased costs of healthcare, and a delay to clinical intervention. This latest clinical research further validates that monitoring with Zio by iRhythm leads to better diagnostic yield and aids in more accurate diagnoses," added iRhythm CEO Quentin Blackford.

12:33 EST AMC says BitPay will be live for online payments by March 19 - AMC Entertainment CEO Adam Aron said via Twitter: "This might rev up the Cryptocurrency fans amongst you. AMC IT says that BitPay will be live for AMC online payments on our web site by March 19, and live on our mobile apps by April 16. Possibly a few days earlier. BitPay, and therefore soon AMC, accepts Doge Coin and Shiba Inu."

12:01 EST Central European Equity falls -17.8% - Central European Equity is down -17.8%, or -$3.33 to $15.42.

12:00 EST Epam Systems falls -33.1% - Epam Systems is down -33.1%, or -$126.49 to $255.94.

12:00 EST JinkoSolar rises 18.6% - JinkoSolar is up 18.6%, or $8.10 to $51.70.

11:45 EST Lordstown Motors down as losses mount, sees raising more funds - Shares of Lordstown Motors (RIDE) are down about 18% in early trading after the company reported Q4 losses per share of 42 cents, which was steeper than the company's loss of 37 cents a share a year earlier. Dan Ninivaggi, CEO of Lordstown, said: "We executed the asset purchase agreement with Foxconn and have made substantial progress on the terms of our contract manufacturing agreement, subject to review by the Committee on Foreign Investment in the US. I believe the Foxconn partnership is a critical step in unlocking the full potential of the Lordstown facility and brings multiple benefits to LMC. Our ongoing discussions with Foxconn are focused on reaching a definitive agreement for the joint development of future vehicles off the MIH platform with an appropriate funding structure to enable us to raise the necessary capital for the success of our partnership." He added on the company's earnings call "Quite frankly, I am disappointed that we're not further along. The relationship with Foxconn is very positive and the discussions are ongoing but we need to bring that to a conclusion and I'm hopeful that we'll get there." Meanwhile, the company noted its continued efforts to raise additional capital to fund the commercial launch of the Endurance. Lordstown CFO Adam Kroll said on the company's call: "We understand that raising additional capital in the near term is critical to the successful launch of the Endurance and the execution of our operating plan." In late morning trading, shares of Lordstown Motors are down about 57c, or 18%, to $2.65.

11:03 EST Discovery confirms plans to appoint Chris Licht to lead CNN - Discovery (DISCA) announced its plans to appoint Chris Licht as the new chairman and CEO of CNN Global. The appointment will be effective following the completion of Discovery, Inc.'s acquisition of WarnerMedia (T), expected in early Q2. Licht has spent more than 20 years in broadcast news and currently serves as executive vice president of special programming at CBS. David Zaslav, incoming CEO of Warner Bros. Discovery, commented: "I have known and admired Chris for more than 15 years and strongly believe he is the best person to lead CNN Global as part of Warner Bros. Discovery. Chris is a dynamic and creative producer, an engaging and thoughtful journalist, and a true news person. He has more than two decades of broadcast experience across local, cable and national news. He has been in the field, in the control room and on the set. He is a highly principled individual who is trusted, hard-working and makes every organization stronger, more innovative, and more cohesive."

10:38 EST EPAM Systems trading resumes

10:34 EST JANA: Zendesk's board 'totally out of touch with shareholder priorities'

10:32 EST JANA Partners sends letter to Zendesk board of directors - JANA Partners LLC sent letter to the Zendesk Board of Directors. The letter says in part: "At Friday's extraordinary shareholder meeting, Zendesk's board received the lowest level of support of any disclosed deal-related shareholder vote (buyer or seller) in the Russell 3000 in the last 20 years (and possibly ever), garnering only 9% support (which would have been even lower excluding the roughly 3% held by management and other insiders).1 This unprecedented rejection of the board's most consequential strategic decision in recent memory comes as no surprise, as we believe it was obvious the Momentive acquisition was flawed from the start. Despite the collapse in Zendesk's share price caused by the announcement of the transaction, widespread rebuke from analysts and investors alike, opposition from independent proxy advisory services and insurmountable odds of winning support, the board nevertheless proceeded full steam ahead in its attempt to acquire Momentive - burning tens of millions of dollars of shareholder capital in the process. We believe it could not be any clearer that Zendesk's board is disengaged and totally out of touch with shareholder priorities, lacks the requisite skillset to govern the company on their behest and/or simply does not care enough to consider them. Thanks to a CNBC report on Friday by David Faber, we have now also learned that Zendesk's board appears to condone unprofessional acts of hostility against dissenting viewpoints. We believe sending an expletive-laden e-mail lashing out at a highly respected, well credentialed CNBC contributor is unacceptable, especially coming from Zendesk's lead independent director, the most powerful independent shareholder representative on the board. Unfortunately for shareholders, this appears to be part of a pattern of hostility towards other points of view. We believe Zendesk requires either significant board change, or in the absence of such change, should be sold. With the Momentive chapter finally in the rearview mirror, we look forward to making the case for shareholders to vote the WHITE proxy card at the Zendesk 2022 annual meeting."

10:06 EST 22nd Century announces South Korea as first VLN international market - 22nd Century Group announced the South Korean tobacco market will be the first international market to commence sales of its VLN reduced nicotine content cigarettes. "The company will continue its launch process in additional markets in Asia and Europe with limited regulatory barriers while also leveraging VLN's MRTP authorization toward seeking approval in additional markets with higher regulatory barriers. In addition to its first international launch of VLN reduced nicotine content cigarettes in the more than $800 billion global tobacco market, 22nd Century Group is actively moving forward to launch VLN in the $80 billion U.S. tobacco market. The U.S. FDA authorized 22nd Century's VLN reduced nicotine content cigarette products on December 23, 2021. The company is currently executing its 90-day post-authorization plan to launch in its first U.S. pilot market," 22nd Century said.

10:04 EST Omega Healthcare, MyndVR announce strategic partnership - MyndVR announced a strategic partnership with Omega Healthcare Investors. As one of the largest REITs in senior care, Omega is committed to bringing technology and innovation to its expanding base of operators across the continuum of care in the US and UK. Omega will make MyndVR's industry-leading portfolio of senior-friendly, therapeutic VR experiences available to nearly 1000 senior living and skilled nursing facilities. This 3-year partnership will offer Omega's valued operators access to MyndVR's vast network of immersive content, VR headsets, and proprietary care tablets, as the exclusive VR partner of Omega with pricing promotions to all Omega operators. The MyndVR platform includes a bundled subscription plan with monthly content updates across a wide variety of reminiscence, music, art, nature-immersion, meditation, and cognitive programs to help seniors achieve their skilled therapeutic goals.

10:01 EST Penn National's 'myheroes' program surpasses 100,000 members - Penn National Gaming is pleased to announce that its "myheroes" program, which honors active-duty military, veterans and first responders, has surpassed enrollment of 100,000 members. In celebration of this milestone, the company has dedicated $100,000 to support local veterans organizations and first responder groups in the communities in which it operates.

10:00 EST AerCap falls -15.7% - AerCap is down -15.7%, or -$9.89 to $52.92.

10:00 EST Seritage Growth Properties rises 10.1% - Seritage Growth Properties is up 10.1%, or 93c to $10.15.

10:00 EST First Horizon rises 30.4% - First Horizon is up 30.4%, or $5.55 to $23.80.

09:47 EST Cano Health falls -9.6% - Cano Health is down -9.6%, or -50c to $4.69.

09:47 EST AerCap falls -10.0% - AerCap is down -10.0%, or -$6.29 to $56.52.

09:47 EST Seritage Growth Properties rises 12.0% - Seritage Growth Properties is up 12.0%, or $1.11 to $10.33.

09:43 EST Amryt Pharma trading resumes

09:38 EST Amryt Pharma trading halted, volatility trading pause

09:31 EST News Corp. completes acquisition of OPIS for $1.15B in cash - News Corp (NWSA) announced that it has completed the acquisition of the Oil Price Information Service and related assets, including the Coal, Mining and Metals business from S&P Global (SPGI) and IHS Markit (INFO). News Corp acquired OPIS for $1.15Bin a cash transaction, subject to customary adjustments (and expects to receive an estimated tax benefit of $180M as part of the transaction1). News Corp also has an agreement to acquire the Base Chemicals business from S&P Global and IHS Markit; that acquisition is expected to close in the coming months. "The OPIS acquisition will significantly enhance our ability to provide high-quality, high-margin professional products in the energy sector, including renewables and carbon benchmarking, for which there is urgent demand from serious companies," said Robert Thomson, CEO of News Corp. "Both OPIS and Base Chemicals are digital and particularly profitable, and we expect their positive financial impact will be obvious to investors. The fact that both sales were required for regulatory approval of the S&P Global and IHS Markit merger ensured that we were able to make the acquisitions for rather attractive multiples."

09:30 EST Soluna Holdings announces debt financing - Soluna Holdings announced a debt financing. On February 22, 2022, the Company issued to certain institutional lenders promissory notes in an aggregate principal amount of $7.5 million for an aggregate purchase price of $7.5 million. The Notes were issued as the first tranche of an aggregate financing of $20.0 million. The Company expects to issue to the Lenders a second tranche of promissory notes in an aggregate principal amount of $2.5 million for an aggregate purchase price of $2.5 million and a third tranche of promissory notes in an aggregate principal amount of $10.0 million for an aggregate purchase price of $10.0 million along with Class D common stock purchase warrants to purchase up to an aggregate of 500,000 shares of common stock of the Company at an exercise price of $11.50 per share. The Warrants will be immediately exercisable for two years upon issuance, subject to applicable Nasdaq Stock Market LLC rules. The Warrants will only be issued if and when the third tranche notes are issued. SHI intends to use the net proceeds of the financing for the acquisition, development and growth of data centers, including cryptocurrency mining processors, other computer processing equipment, data storage, electrical infrastructure, software and real property, and business, and for working capital and general corporate purposes, which include, but are not limited to, operating expenses.

09:25 EST Diana Shipping announces direct continuation of time charter contract - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Cargill International S.A., Geneva, for one of its Kamsarmax dry bulk vessels, the m/v Medusa. The gross charter rate is US$26,000 per day, minus a 4.75% commission paid to third parties, for a period until minimum May 15, 2023 up to maximum July 15, 2023. The new charter period is expected to commence on March 5, 2022. The m/v Medusa is currently chartered, as previously announced, at a gross charter rate of US$11,000 per day, minus a 4.75% commission paid to third parties. The "Medusa" is a 82,194 dwt Kamsarmax dry bulk vessel built in 2010. The employment of "Medusa" is anticipated to generate approximately US$11.18 million of gross revenue for the minimum scheduled period of the time charter.

09:24 EST WISeKey launches upgraded WISeID Cloud - WISeKey Holding announced at the Mobile World Congress Swiss Pavilion the launch of its upgraded WISeID Cloud Storage service. Digital Identification based Sovereign Cloud is one of several technologies, including semiconductors and AI that WISeKey provides where the EU is keen to build its indigenous capabilities. Currently, the public cloud landscape is dominated by US providers, all of which are growing their share of the European market. EU is seeking to develop a native cloud ecosystem and reduce this reliance on overseas companies. Last year, 25 member states signed a declaration pledging to build the next generation of cloud technology in Europe, and various initiatives are already underway. WISeID Cloud is fully compliant with the EU New Data and Cloud Alliance which offers a broader push toward digital sovereignty, and it is intended to reduce dependencies from foreign technology providers. As concrete step towards this support, WISeKey already operates a Swiss-EU based WISeID Cloud Storage service www.wiseid.com.

09:22 EST Amryt Pharma: FDA says cannot approve Oleogel-S10 NDA in current form - Amryt announced it has received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for Oleogel-S10, for the treatment of the cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa, a rare, genetic skin disease characterized by extremely fragile skin that blisters and tears from minor friction or trauma for which there are no approved treatment options. The FDA communicated that it had completed its review of the application and has determined that the application cannot be approved in its present form. The FDA has asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in EB. Amryt intends to discuss with the FDA the nature of the data required to address the Agency's concerns. Dr Joe Wiley, CEO of Amryt Pharma, commented: "We are extremely disappointed by this decision and we remain committed to our goal of bringing Oleogel-S10 to patients. EB is a devastating disease with no approved treatment options and the EB community is desperate for a therapy. The EASE study was the largest randomized clinical trial ever conducted in this disease and the first Phase 3 study to meet its primary endpoint. We are committed to working collaboratively with the FDA to identify the most expeditious pathway towards a potential approval for this important therapy."

09:21 EST Akari Therapeutics announces data on nomacopan in treatment of trauma - Akari Therapeutics announced new data showing that clinical outcomes in U.S. Army trauma patients correlate with complement activation, and that nomacopan significantly improves survival from 30% to 80% in a clinically relevant preclinical model of traumatic hemorrhage. Traumatic hemorrhage is the leading cause of potentially preventable deaths that occur during the pre-hospital phase of care. Current treatments still largely rely on organ/tissue supportive approaches and fluid resuscitation, and no effective pharmacological therapeutics are available. Identifying new life-supporting treatment focused on the interval between point of injury to hospital is a key objective. Military blast injury accounted for 70%-80% of U.S. casualties in Iraq and Afghanistan, while in the U.S. there are approximately 500,000 civilian trauma hospital discharges a year which are defined as severe and could benefit from early drug intervention to reduce multi-organ dysfunction. Annual inpatient trauma-related hospital costs in the U.S. are approximately $30 billion a year. An analysis of 54 military trauma patients in Baghdad with blast and gunshot injury showed that three key markers of complement activation - C5a, C5b9 and Bb - were elevated 300%-600% in the first eight hours after the traumatic event, compared to healthy controls. In addition, pro-inflammatory C5a and C5b9 plasma levels correlated with trauma severity, and complement activation correlated with clinical outcomes. Nomacopan's mode of action may be particularly suited for treatment of TH as critically it inhibits terminal complement activation via all three complement pathways and additionally inhibits leukotriene B4 which is also implicated in exacerbation of TH. To test the anticipated efficacy of nomacopan, a clinically relevant pre-clinical model of blast injury and hemorrhagic shock was undertaken by the United States Army Institute of Surgical Research. The addition of nomacopan to damage control resuscitation protocol, significantly inhibited terminal complement activity, decreased local and systemic inflammatory responses, improved hemodynamics and metabolism, attenuated tissue and organ damage and increased survival. Nomacopan's therapeutic efficacy in this model of TH is likely a result of the drugs inhibition of multiple inflammatory pathways primarily: Inhibiting C5 and thereby preventing its cleavage into C5a and C5b9, both potent inflammatory mediators correlated with trauma severity. Significantly reducing levels of key pro-inflammatory cytokines and the inflammatory mediator HMGB1 that were elevated post trauma in both patients and the pre-clinical model. Binding to and thereby removing LTB4 from circulation and disrupting neutrophil tissue swarming, a key component of trauma. Nomacopan is particularly well suited for pre-hospital use in both a battlefield/military or ambulance/ civilian setting due to the molecules thermostability and ease of administration. In addition, nomacopan is fast acting and clears the body within a matter of days is also important in that the optimal window for treatment by inhibiting complement is likely to be the first 24 hours following TH. The planned next steps include an extension study following on from the reported USAISR program. Also, in parallel, a collaboration for a UK observational study with civilian traumatic brain injury patients to optimize the nomacopan clinical treatment regimen leading to a potential clinical study that could include both military and civilian patients.

09:18 EST AVCtechnologies announces securities purchase agreement - American Virtual Cloud Technologies announced that it has entered into a securities purchase agreement for a sale of equity securities to an institutional investor. The net proceeds, after original issue discount, will total $15 million initially, plus an additional $5 million subject to the satisfaction of certain conditions, including receipt of stockholder approval pursuant to Nasdaq listing rules. AVCT will issue shares of a new series of convertible preferred stock, together with warrants, pursuant to the terms of the securities purchase agreement. AVCT previously announced a definitive agreement to sell its Computex business to Calian Group, a move that will transition AVCT to a pure-play cloud communications and collaboration company, centered on its premium Kandy cloud-based, real-time communications platform The Company expects that this security sale and the expected net proceeds from its planned divestiture of its Computex business will be used to retire all of its existing debt.

09:16 EST Verra Mobility files SEC form 12B-25, provides business update - Verra Mobility announces its filing of a Form 12b-25 with the Securities and Exchange Commission to disclose that it will not be able to file its Form 10-K by its due date of March 1, 2022, and is not expected to do so within the 15-day extension period allowed by the Form. During its year-end 2021 financial statement review process, Verra Mobility determined that revenues from the Company's recently acquired Australian subsidiary, Redflex Holdings Limited, may not have been recorded in accordance with generally accepted accounting principles. The Company's Audit Committee is conducting an investigation of the circumstances surrounding these issues to determine, among other things, whether any related adjustment is necessary for the previously issued financial statements for the second and third quarters of fiscal year 2021. The Company will also delay its fourth quarter and fiscal 2021 earnings release and investor conference call, previously scheduled for February 28, 2022. The Company will make a further announcement in a subsequent press release to reschedule the date and time of the earnings conference call. "We are currently reviewing certain transactions to determine if revenue has been recognized in the proper period, and to ensure proper accounting in the future." said David Roberts, Verra Mobility's president and chief executive officer. "We are focused on delivering timely, accurate and transparent financial reporting, and we will require additional time in order to fully complete our analysis. This review is related to the Company's recently acquired Redflex operations, with no impact to cash, and no impact on our business outlook, which continues to be strong."

09:15 EST Momentive announces cooperation agreement with Legion Partners - The Company has entered into a cooperation agreement with Legion Partners, a significant stockholder of Momentive. As part of the agreement, the Company will appoint Legion's Sagar Gupta to the Momentive Board of Directors, and he will serve as a member of the Board's Strategic Committee, which will continue to oversee and direct the Company's strategic review. Under the agreement, Legion has agreed to vote its shares in favor of the Momentive Board's nominees at the 2022 annual meeting, as well as other customary standstill provisions. Separately, Brad Smith, who has served on the Momentive Board since 2017, was recently named President at Marshall University and will be stepping down as a director. In addition, the Company will also take the following actions to further enhance its corporate governance: Momentive stockholders will vote at the 2022 annual meeting to approve an amendment to the Company's certificate of incorporation to declassify the Board and, subject to approval of the amendment, the Company will begin to declassify the Board and allow for the annual election of directors beginning with the 2022 annual meeting; and The Board will implement a majority voting standard in uncontested elections of directors, where directors would be elected if they receive more votes in favor than against, and each incumbent director will submit an irrevocable, conditional offer of resignation effective if such director fails to receive a majority vote in favor of their election. The full agreement between Momentive and Legion, as well as additional details regarding the governance changes, will be filed with the Securities and Exchange Commission.

09:13 EST Momentive promotes Priyanka Carr to COO - Priyanka Carr has been promoted from general manager of the market research business to the role of chief operating officer, reporting to CEO Zander Lurie. Pri will lead the functions responsible for building great products, bringing them to market, and driving Momentive's scaled product-led growth motion. The Company believes that unifying these functions under one leader will enable more customer-centric product innovation. Tom Hale will be leaving after nearly six years. Under Tom's leadership, the Company scaled its operations and expanded its sales-assisted motion. Momentive is grateful for Tom's partnership and wishes him well in his next chapter. Pri joined Momentive in 2014 and most recently served as the general manager of the Company's market research business. Previously, she led the Company's strategy, corporate development, and partnerships function. Prior to joining Momentive, Pri led teams at Bain & Company in its technology, media, telecommunication, and private equity practices.

09:12 EST Momentive announces $200M share repurchase program - Momentive outlined its plans to leverage the strengths of its products, its hybrid go-to-market strategy, and its strong financial profile to accelerate value creation for stockholders. As part of this plan, the Company announced changes to its Board of Directors and the Board's Strategic Committee, and that it has authorized a $200 million share repurchase program.

09:11 EST Teladoc up 13% after launching virtual care offering on Amazon's Alexa - Shares of Teladoc Health (TDOC) are sharply higher in pre-market trading after the company announced a "first of its kind experience" with Amazon Alexa (AMZN) with the launch of voice-activated general medical virtual care on supported Echo devices. "Customers in the U.S. will now be able to connect with a Teladoc care provider 24/7 from supported Echo devices for general medical needs. Teladoc on Alexa will initially launch via audio with video visits coming soon," said Teladoc. Following the news, Teladoc shares are up $9.46, or 13%, to $80.20 in pre-market trading.

09:10 EST Celsion receives $1.4M from sale of New Jersey NOLs - Celsion Corporation announced it has received $1.4 million in net cash proceeds from the sale of approximately $1.5 million of its unused New Jersey net operating losses. The NOL sales cover the tax year 2020 and are administered through the New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer program. This non-dilutive funding adds to the over $55 million in gross proceeds from equity offerings completed in 2021, further strengthening the Company's balance sheet. The Company plans to sell an additional $3.5 million of unused New Jersey NOLs available to the Company under the program over the next 3 years. Based on current budget projections, Celsion anticipates the current cash balance coupled with future sales of its unused NOLs to be sufficient to fund the Company's operations and clinical development programs through 2024. The Technology Business Tax Certificate Transfer administered by the NJEDA enables qualified companies to sell up to $20 million of their unused New Jersey net operating losses and R&D tax credits to unaffiliated, profit-generating corporate taxpayers in the state of New Jersey. The economic development program is designed to allow technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund more R&D, expand its workforce, and cover other allowable expenditures. Celsion is one of several biotechnology/technology companies to qualify in this competitive process to share in the funding this year.

09:09 EST Adtalem Global Education appoints Cheryl James as chief HR officer - Adtalem Global Education has appointed Cheryl James as senior vice president, chief human resources officer, effective immediately. In her role, James is responsible for leading the company's centralized human resources organization and for guiding the attraction, retention and development of talent across Adtalem and its family of institutions. "I am excited to welcome Cheryl to Adtalem and the leadership team. Cheryl brings more than 30 years of HR leadership experience to the organization and has implemented proven strategies that enrich cultures, empower employees and drive overall organizational effectiveness," said Steve Beard, president and CEO. "Cheryl joins us at a pivotal time in the company's history, as we fully shift our focus to healthcare education, and during a highly competitive time for talent. We are thrilled to benefit from the years of leadership experience Cheryl brings to our team."

09:08 EST Teladoc Health, Amazon partner to launch Teladoc on Alexa - Teladoc Health (TDOC) announced a first of its kind experience with Amazon Alexa (AMZN) with the launch of voice-activated general medical virtual care on supported Echo devices, such as an Echo, Echo Dot, and Echo Show. Customers in the U.S. will now be able to connect with a Teladoc care provider 24/7 from supported Echo devices for general medical needs. Teladoc on Alexa will initially launch via audio with video visits coming soon.

09:06 EST Verisk says 47 insurers commit to contributing to Statistical Database in 2022 - Verisk's insurance database has broken its growth record for the second consecutive year. An additional 47 property/casualty insurers have committed to contributing their premium and loss records in 2022, gaining access to critical analytics from Verisk's industry-leading ISO Statistical Database. In 2020, 37 insurers joined Verisk's statistical database. Last year, that number increased to 47 new insurers, including global, national, super-regional and regional companies-making it the most new participants to join over the past 10 years. These new contributors are expected to significantly increase the size of the statistical database's aggregated records across its wide range of personal and commercial lines of business.

09:05 EST Pacific Biosciences supports SickKids to investigate use of HiFi sequencing - PacBio announced it will be supporting The Hospital for Sick Children in Toronto, Canada in using HiFi whole genome sequencing to potentially identify genetic variants that may be associated with medical and developmental conditions. Samples that will be examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology, but still lack the identification of a disease-causing variant. SickKids will use HiFi WGS to analyze samples from research participants who are highly suspected to have a genetic condition but have not yet received a diagnosis despite previous genetic testing, including srWGS. The team will explore whether HiFi WGS can detect potential genetic causes for a range of conditions, such as autism spectrum disorder and congenital diseases.

09:04 EST Sellas announces final court approval of settlement of securities litigation - SELLAS Life Sciences Group announced that on February 24, 2022 the United States District Court for the District of New Jersey issued final approval of the settlement of the claims relating to the Company's predecessor, Galena Biopharma, Inc., in the litigation captioned In re Galena BioPharma, Inc. Securities Litigation. The settlement provides for the payment of $1,600,000 to a settlement fund which is to be distributed to members of the plaintiff class after accounting for fees and expenses, which amount is fully covered by insurance.

09:01 EST STMicroelectronics introduces third generation of MEMS sensors - STMicroelectronics is introducing its third generation of MEMS sensors. The new sensors enable the next leap in performance and features for consumer mobiles and smart industries, healthcare, and retail. MEMS technology is the cornerstone of the robust and chip-sized motion and environmental sensors that drive the intuitive context-aware features of today's smartphones and wearables. ST's latest generation MEMS sensors now take performance to a new level, going beyond established technical limitations on output accuracy and power consumption. The new sensors can deliver the highest accuracy for product features such as activity detection, indoor navigation, and precision industrial sensing. At the same time, they keep battery demand low for longer runtimes. Extra features, to be included in selected variants, include ST's machine-learning core and electrostatic sensing. The MLC brings adaptive, machine-learning capabilities to edge applications that operate at extremely low power. The charge-variation sensing channel monitors changes in electrostatic charge, either through contact with the body in a smartwatch or fitness band or by non-contact sensing. ST MEMS sensors with QVAR can enhance user-interface controls, to ensure seamless interactions, or to simplify detection of moisture and condensation. Radar-mode applications include human-presence detection, activity monitoring, and people counting.

09:00 EST NFI Group's ADL welcomes ScotZEB funding for 137 zero-emission buses - NFI Group subsidiary Alexander Dennis welcomed the Scottish Government's announcement of the award of GBP 62M in funding to bus operators through Phase 1 of the Scottish Zero Emission Bus Challenge Fund. The aim of ScotZEB is to encourage significant change in the bus market in favour of zero-emission technologies, creating sustainable and inclusive growth. By supporting the swift transition to zero-emission vehicles and infrastructure, the fund aims to help achieve targets to reduce greenhouse gas emissions, contribute to the delivery of Low Emission Zones, encourage inward investment and growth in the supply chain of zero-carbon vehicle and energy solutions in Scotland, with associated employment, economic and social benefits.

08:58 EST Grid Dynamics expands footprint to India - Grid Dynamics announced the creation of Grid Dynamics India via a strategic partnership with Cygnet Infotech. Extending its footprint in South Asia represents the next stage of Grid Dynamics' global expansion. It allows the company to service clients across fifteen time zones, strengthen its capabilities, and expand collaboration with innovative technology partners worldwide. The partnership represents the first of several expansion phases that Grid Dynamics is planning in South Asia for 2022 and beyond.

08:57 EST Medspresso joins Speciality Coffee Association of South Africa - WUHAN GENERAL GROUP is pleased to share the following update: Medspresso is pleased to announce its membership in the Speciality Coffee Association of South Africa. SCASA is a non-profit organization that brings together coffee industry participants from various sectors in Southern Africa. Its objective is to promote the appreciation of high-quality coffees as well as the recognition of coffee industry workers in Southern Africa. The organization's goal is to grow the South African coffee market and support all stakeholders through its motto of a "United Passion for Coffee", including the commitment to quality, the spirit of cooperation, sensitivity to the environment, and the consciousness of social issues. SCASA is a representative for the World Coffee Events and the World Barista Competition and promotes contests associated with these organizations.

08:54 EST Blonder Tongue Laboratories announces DRAKE PEG Encoder Line - Blonder Tongue Laboratories announced the introduction of their next generation of IP video encoders, the DRAKE PEG 2+. Expanding on the best-selling DRAKE PEG PLUS product line, the Drake PEG 2+ is an advanced two-channel video encoder focused on the Public, Education and Government and House of Worship market segments. The DRAKE PEG 2+ brings HEVC and Adaptive Bit-Rate encoding technology to the PEG product line along with SRT technology for open internet based backhaul of video and audio.

08:53 EST Aemetis unveils 2022 five-year plan targeting $1.5B revenue by 2026 - Aemetis released the 2022 Five Year Plan that projects the company will generate $1.5 billion in revenues and $461 million of adjusted EBITDA in year 2026. The Revenues plan reflects a projected compound annual growth rate of 39% and the EBITDA plan reflects a projected compound annual growth rate of 79% for the years 2022 to 2026. The Aemetis 2022 Five Year Plan will be presented at the Credit Suisse Vail Energy Conference on Monday, February 28th at 10 a.m. Eastern time by Eric McAfee, the Chairman and CEO of Aemetis. The presentation will be available at www.aemetis.com and will be filed with the SEC under Form 8-K. The conference presentation by Mr. McAfee will focus on negative carbon intensity Renewable Natural Gas, sustainable aviation fuel and renewable diesel fuel produced using carbon sequestration of CO2, and additional low- and below-zero-carbon products from the Aemetis ecosystem of renewable projects. Aemetis has signed offtake agreements with an aggregate value of up to approximately $5.7 billion for these products during the past year. "Despite external pandemic and regulatory issues this past year, Aemetis successfully executed in line with the first year of the 2021 Five Year Plan, and we are providing the 2022 Five Year Plan to provide additional insight into the growth of the company through 2026," said Eric McAfee, Chairman and CEO of Aemetis. "Significant milestones were achieved in the past year by Aemetis, including: completed seven more miles of RNG pipeline; completed construction of the biogas-to-RNG upgrading facility; completed construction of the PG&E gas pipeline interconnection unit; commenced construction of five dairy digesters with H2S removal units which are now being completed; signed the acquisition of the 125-acre Riverbank Industrial Complex with 100% renewable electricity, a rail line and storage for 120 railcars, 710,000 s.f. of buildings, and 50 acres of open land for construction of the Carbon Zero 1 renewable jet/diesel plant and carbon sequestration facilities; signed SunPower and Schneider Electric to construct a 1.9 megawatt solar microgrid with battery backup; completed construction and successfully tested the Mitsubishi ZEBREX electric ethanol/water separation facility; completed installation of five stainless steel tanks with 275,000 gallons of additional ethanol process tank capacity to support the operation of carbon reduction systems; and engineered the Mechanical Vapor Recompression unit at the Keyes plant to utilize low carbon intensity solar and grid electricity instead of petroleum natural gas." In the 2022 Five Year Plan, the Company's revenue growth is primarily expected from dairy Renewable Natural Gas, the Aemetis "Carbon Zero" renewable jet/diesel plant, and two carbon sequestration CO2 injection wells installed near the California biofuels plant sites. The Aemetis Dairy RNG project plan shows projected revenues growing from $9.5 million in 2022 to $217 million in 2026, while Dairy RNG project EBITDA is expected to expand from $1.6 million in 2022 to $185 million in 2026. The plan includes the delays related to the regulatory process to obtain LCFS credit pathway approvals for each dairy digester. Aemetis has been awarded $23 million of grants related to dairy RNG and related gas cleanup and utility pipeline interconnection units, including a $1 million grant to install an RNG dispensing station to fuel RNG trucks at the Keyes plant. The projected $217 million of dairy RNG revenues in year 2026 represents less than one percent of the addressable market for negative carbon intensity RNG, with a projected increase in demand for Aemetis -426 carbon intensity RNG to produce electricity to power the expected growth of heavy electric vehicles such as cargo trucks, buses, waste haulers and drayage trucks. The Aemetis "Carbon Zero 1" renewable jet/diesel plant is planned to generate $623 million of revenues and $147 million of adjusted EBITDA in year 2026. By completing carbon reduction upgrades and expansions of its current operating ethanol and biodiesel plants, the Company expects to generate annual revenue in ethanol and biodiesel of approximately $560 million by 2026, up from about $283 million of expected revenue in 2022, an increase of 98%.

08:50 EST Expedia, IHG Hotels & Resorts in optimized distribution preferred partnership - Expedia Group and IHG Hotels & Resorts announced that Expedia Group is now a preferred redistributor of IHG Hotels & Resort properties' wholesale rates through Expedia Group's Optimized Distribution Preferred program. The wholesale distribution market is inefficient and expensive. The complexity of maintaining disparate channels takes a significant chunk out of hotels' bottom line. Expedia Group's Optimized Distribution program resolves these challenges by creating a primary gateway solution for the hotelier and its B2B demand partners, ultimately reducing costs, generating incremental revenue for hotels, and providing accurate content and better rates to travelers. IHG Hotels & Resorts joins a growing list of renowned hotel chains to partner with Expedia Group on its Optimized Distribution program on a preferred basis. The Optimized Distribution program, provided by Expedia Group, is redefining and expanding the scope and scale of wholesale distribution in the hotel industry. Expedia Group's network expands the scope of the wholesale market, connecting hotels to B2B demand partners, including a range of third-party travel providers as well as tour operators and travel agents. IHG will leverage Expedia Group's industry-leading platform to consolidate and simplify its wholesale distribution. "We are thrilled to join Expedia Group's Optimized Distribution Program," said George Turner, Chief Commercial & Technology Officer, IHG Hotels & Resorts. "This arrangement will enable us to more seamlessly manage our wholesale distribution by providing cost savings, better control over our channel mix and enhancements to our revenue management strategy, ultimately driving additional value for our owners and hotels."

08:47 EST Veracyte appoints Annie McGuire as General Counsel - Veracyte announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company's legal functions and will report to Marc Stapley, Veracyte's chief executive officer.

08:44 EST IntriCon to be acquired by Altaris Capital affiliate for $241M - Intricon Corporation announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, an investment firm focused exclusively on the healthcare industry, will acquire the company. Under the terms of the agreement, Altaris will acquire all outstanding shares of Intricon for $24.25 per share in a transaction that values Intricon at an equity value of approximately $241 million. The purchase price represents a meaningful premium of approximately 39% to Intricon's closing stock price on February 25, 2022.

08:43 EST Consolidated Water notes recent increase in water demand in Cayman Islands - Consolidated Water has noted a recent increase in water demand in the Cayman Islands as the country's Phase 5 reopening plan continues. The company operates seven seawater desalination plants that produce all the piped drinking water on Grand Cayman, which is home to about 95% of the nation's population. On February 18, the Cayman Islands government dropped all on-island COVID testing for vaccinated travelers, citing a decline in local infection cases. The Islands also no longer require post-arrival COVID-19 tests for fully vaccinated travelers, and has reduced the quarantine period for partially vaccinated and unvaccinated individuals from 10 to seven days. Major airlines, including American Airlines and United Airlines, resumed their flight routes to Cayman earlier this month. Tourism minister, Kenneth Bryan, said that next month Delta and Southwest will also resume their flights, and Cayman Airways will resume its service to Denver, Colorado.

08:41 EST Minerva announces publication of Roluperidone Phase 3 study results - Minerva Neurosciences announced that results from the Phase 3 clinical trial of roluperidone to treat negative symptoms in patients with schizophrenia have been published in Schizophrenia Bulletin. The study authors conclude that this study confirms the potential of roluperidone to treat the negative symptoms in individuals with schizophrenia as well as improve everyday functioning. The publication, entitled, "Efficacy and Safety of Roluperidone for the treatment of negative symptoms of schizophrenia," reports on the Phase 3 placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2 and alpha1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. The goal of the trial was to confirm the findings of a previous Phase 2 trial with a similar patient population and methodology that had demonstrated roluperidone superiority over placebo. The Company previously disclosed results of the Phase 3 trial of roluperidone in May 2020 and open-label results in May 2021. The Phase 3 study included 513 patients with schizophrenia with moderate to severe negative symptoms. Study patients were administered either 32 mg/day of roluperidone, 64 mg/day of roluperidone, or placebo for 12 weeks. The primary endpoint was the PANSS-derived Negative Symptom Factor Score and the key secondary endpoint was Personal and Social Performance scale total score. The study found that NSFS scores improved for patients receiving roluperidone 64 mg compared to placebo. The intent-to-treat analysis data set marginally missed statistical significance, but reached nominal significance for the modified-ITT data set. Changes in PSP total score were statistically significantly better on roluperidone 64 mg compared to placebo for both ITT and m-ITT.

08:39 EST Ageagle Aerial Systems to showcase eBee TAC UAS at Tough Stump Tech Demo - AgEagle Aerial Systems announced that the eBee TAC Unmanned Aerial System, pioneered by AgEagle subsidiary senseFly, will be showcased today at Tough Stump Technologies' Tech Demo Day in North Carolina for invited government and military officials. Since 2018, Tough Stump Technologies and senseFly have teamed on the development of the Aerial Reconnaissance Tactical Edge Mapping Imagery System, a turnkey sUAS kit designed to rapidly collect and analyze high-resolution imagery, filling critical gaps in situational awareness and intelligence collection for defense, intelligence and civil organizations. In August 2021, the new eBee TAC was integrated into ARTEMIS - delivering tactical mapping users a purpose-built drone system to readily incorporate into their existing workflows.

08:38 EST Semrush plans acquisition of Austin-based Kompyte, no terms - Semrush announces plans to acquire competitive intelligence automation and sales enablement platform Kompyte. Based out of Austin, Kompyte is an AI-driven solution designed to simplify the tracking, compilation and analysis of competitor insights for sales, marketing, product development and executive teams. Its platform delivers timely, strategic insights derived through the consistent monitoring of competitors' holistic online presence. This enables better messaging, positioning, product development, and revenue capture for both small teams and large enterprises. "We were always looking for a MarTech product that uses market data to bring other teams to the table," said Eugene Levin, Chief Strategy and Corporate Development Officer at Semrush. "Kompyte is exactly that and can be used by almost every department: marketers can monitor the best campaigns across their industry to find inspiration, product teams can monitor critical feature updates of their competitors and changes in pricing, and sales teams can use battle cards to improve their win rate vs. other industry players." The acquisition will expand Semrush's ability to help its customers beyond their marketing departments, especially considering 88% of Kompyte's total user base falls within sales organizations. Existing and future customers can optimize their sales efforts and achieve higher win rates in competitive deals using tools like battle cards, which provide virtually real-time information about how their product or service compares to their competitors.

08:36 EST Heidrick & Struggles appoints Nelson-Hurt as Chief Diversity Officer - Heidrick & Struggles (HSII) announced it has appointed Cecilia Nelson-Hurt as its new Chief Diversity Officer, effective immediately. Nelson-Hurt joins the firm from L'Oreal USA (LRLCY), where she served as Vice President, Diversity, Equity & Inclusion.

08:34 EST Safe-T launches Net Bridge - Safe-T Group announced the launch of Net Bridge, its latest social responsibility program. Powered by the Company's global IP proxy and data collection technologies, the Net Bridge social responsibility program will provide pro-bono services and access to its network in order to support both academic and nonprofit research initiatives that aim to create positive global impacts and change. Safe-T's advanced technology can be utilized in a wide range of market research activities including the detection and identification of criminal organizations, violations of human rights and human trafficking, as well as health and environmental issues under programs currently run by nonprofit universities and academic institutions as well as law enforcement organizations. The Net Bridge program is directed by Safe-T's Enterprise Privacy unit through a newly established team of partnerships. The Net Bridge program is the latest social responsibility program launched by Safe-T Group, building upon previous efforts that include the donation of free remote access services for employees of organizations affected by COVID-19.

08:34 EST Metals Company welcomes leaders' recognition of deep-sea nodules - The Metals Company commended Western political and military leaders for their growing acknowledgement of the potential for seafloor polymetallic nodules to bolster domestic critical mineral supply chains for the clean energy transition. Seventeen high-ranking U.S. military officers including former Director of National Intelligence Admiral Dennis Blair said in a letter to the U.S. Secretary of Defense, "The national security imperative of creating sufficient mineral supplies to build future EVs, energy infrastructure from turbines to transmission, and modern aerospace and defense systems must include a robust and secure supply chain within U.S. control." Meanwhile as part of its Vision 2030 investment plan, the French Government is investing over 300 million euros to support deep-sea exploration for polymetallic nodules. During the One Ocean Summit last week, France's Secretary General for the Sea, Denis Robin, reaffirmed the country's commitment and said that recent calls for a moratorium on such activities would mean maintaining a "veil of ignorance" on what happens deep below the ocean's surface, adding: "There is nothing that justifies stopping us gathering this information." Last October, French President Emmanuel Macron said deep-sea exploration was an essential part of understanding life in these remote regions, which could also provide "access to certain rare metals". France holds two seafloor minerals exploration contracts with the International Seabed Authority: a polymetallic nodule contract in the Clarion Clipperton Zone of the Pacific Ocean and a polymetallic sulphides contract in the Mid-Atlantic Ridge. France's commitment to invest in deep-sea exploration echoes similar investments by a number of other sovereign states. Last July, the Indian Government under President Modi allocated $600 million over the next five years for its 'Deep Ocean Mission', including investments to undertake the necessary resource definition work on its polymetallic nodule contract area in the Central Indian Ocean Basin (CIOB) and to develop an integrated nodule collection system. Investment in deep-sea exploration is also a national priority in China, which holds three polymetallic nodule contracts in the CCZ, more than any other country. Other countries that directly hold exploration contracts or sponsor private company contracts in the CCZ include the United Kingdom, Belgium, Jamaica, the Republic of Korea, and Russia, as well as TMC's sponsoring states, the Republics of Nauru and Kiribati, and the Kingdom of Tonga.

08:30 EST Intricon trading halted, news pending

08:29 EST Microchip announces SuperFlash memBrain solution - Microchip Technology announced that its SuperFlash memBrain neuromorphic memory solution has solved this problem for the WITINMEM neural processing SoC, the first in volume production that enables sub-mA systems to reduce speech noise and recognize hundreds of command words, in real time and immediately after power-up. Microchip has worked with WITINMEM to incorporate Microchip's memBrain analog in-memory computing solution, based on SuperFlash technology, into WITINMEM's ultra-low-power SoC. The SoC features computing-in-memory technology for neural networks processing including speech recognition, voice-print recognition, deep speech noise reduction, scene detection, and health status monitoring. WITINMEM, in turn, is working with multiple customers to bring products to market during 2022 based on this SoC.

08:26 EST First Wave BioPharma announces $9M registered direct offering - First Wave BioPharma announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 6,498,195 shares of its common stock and warrants to purchase up to an aggregate of 6,498,195 shares of common stock at an effective purchase price of $1.385 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.26 per share, are exercisable immediately, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about March 2, 2022, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The Company also has agreed that certain warrants to purchase an aggregate of 1,459,593 shares of common stock of the Company that were issued to such investor in January 2021 and March 2021, as applicable, will be amended to have a reduced exercise price of $1.26 per share and the term of exercise will be extended to March 2, 2027, at a purchase price of $0.0281 per amended warrant. The gross proceeds from the offering are expected to be approximately $9 million. The Company intends to use the net proceeds from the offering to pay a portion of the cash purchase price for its acquisition of First Wave Bio, Inc. and for other general corporate purposes, which may include product manufacturing, clinical development and/or increases in working capital.

08:26 EST Osisko Development announces drilling results from San Antonio project - Osisko Development is pleased to announce the final drilling results from the 2021 exploration and category conversion drill program campaign at its San Antonio Project in Sonora State, Mexico. The Company is also pleased to report, further to its previously-announced non-brokered private placement of up to US$110 million of subscription receipts of the Corporation, that the Corporation expects to close a first tranche of the Non-Brokered Placement on March 4, 2022 for gross proceeds of approximately US$67.3 million of Subscription Receipts. The Corporation has also received subscription proceeds or expressions of interest for the remaining Subscription Receipts allotted under the up to US$110 million Non-Brokered Placement, which Osisko Development expects to close, as a second tranche closing, in late March 2022. The Non-Brokered Placement is being completed on a "non-brokered" basis and no commission or finder's fee will be paid by Osisko Development in connection therewith. San Antonio Drill Results Summary: A total of 27,900 meters were drilled in 177 holes in 2021. The objective of the drill program was to conduct exploration and resource drilling at a spacing of 25 meters and historic drilling validation for the three main target areas. This news releases encompasses all 6,550 meters in 33 holes from the Golfo de Oro Target: GO-DD-21-015 to GO-DD-21-174 inclusive and the remaining assays from 8,050 meters in 76 holes at Sapuchi: SP-DD-21-060A to SP-DD-21-173 inclusive. Assay highlights from Golfo de Oro include 1.55 g/t Au and 2.32 g/t Ag over 42.50 meters in hole GO-DD-21-111 and 2.47 g/t Au and 18.67 g/t Ag over 21.20 meters in hole GO-DD-21-057 including a sample of 18.00 g/t Au and 43.90 g/t Ag over 1.50 meters within the prospective hydrothermal breccia. Assay highlights from Sapuchi include 2.19 g/t Au and 4.12 g/t Ag over 78.90 meters in hole SP-DD-21-102 including a high-grade sample of 21.30 g/t Au and 11.75 g/t Ag over 3.20 meters. A total of 18 intervals below assayed greater than 1.00 g/t Au over at least 10.0 meters. Gold mineralization is hosted within altered hydrothermal breccia and sediments, as stockwork quartz veins and veinlets and adjacent to intrusions and fault structures. Sean Roosen, CEO of Osisko Development commented, "The 2021 diamond drill campaign at our San Antonio Project was successful in defining and expanding the known zones as shown by these recent results. The Sapuchi, Golfo de Oro, and California Zones trend for approximately three kilometers and there are at least a dozen other targets at surface that remain unexplored or underexplored along a ten kilometer strike. These results will be incorporated into the mineral resource estimate and used to further determine our next steps for expansion on the project."

08:23 EST Jasper Therapeutics appoints Ronald Martell as CEO - Jasper Therapeutics announced the appointment of Ronald Martell as the company's Chief Executive Officer effective March 15, 2022. Prior to joining Jasper, Mr. Martell served as the President and CEO of MorphImmune, Inc., a private platform company advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system.

08:22 EST Astellas Pharma, Seagen announces CHMP confirms positive opinion for PADCEV - Astellas Pharma (ALPMY) and Seagen (SGEN) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has confirmed its previously adopted positive opinion, recommending approval of PADCEV as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and a PD-1/L1 inhibitor. The CHMP initially adopted a positive opinion of enfortumab vedotin on December 16, 2021, providing its recommendation to the European Commission (EC) for a final decision. During the EC's decision-making process, further safety information was brought to the attention of the CHMP. Following a request from the EC and taking into account the latest information, the CHMP re-adopted its positive opinion.1 If approved by the EC, enfortumab vedotin will be the first antibody-drug conjugate authorized in the European Union for people living with advanced urothelial cancer. The positive opinion from the CHMP will now be reviewed by the EC. EC decisions are valid in the European Union Member States, as well as Iceland, Norway and Liechtenstein.

08:18 EST Blueprint Medicines, Proteovant Therapeutics announces strategic collaboration - Blueprint Medicines Corporation and Proteovant Therapeutics announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need. The collaboration will bring together Proteovant's Artificial Intelligence-enhanced targeted protein degradation, TPD, platform and Blueprint Medicine's precision medicine expertise to discover novel targeted protein degraders. The companies will jointly research important targets and advance up to two novel protein degrader therapies into development candidates. As a core part of the collaboration, Proteovant's exclusive partner for TPD, VantAI, will deploy its leading AI technologies for degrader generation and optimization. Upon designation of a clinical development candidate, Blueprint Medicines has the exclusive option to develop and commercialize products resulting from the collaboration. Proteovant has the option to co-develop and co-commercialize the second of the two Blueprint Medicines-optioned programs in the U.S. Subject to the terms of the agreement, Proteovant will receive a $20M upfront payment and will be eligible to receive up to an additional $632M in potential research, development, regulatory and commercialization milestone payments plus tiered royalties from mid- to high-single digits on net sales on the first two program targets, subject to adjustment in specified circumstances. Of the total contingent payments, up to $105M would be preclinical, clinical development and regulatory milestones and up to $527M would be approval and sales milestones.

08:16 EST BriaCell adds two clinical trial sites in Phase I/IIa study of Bria-IMT - BriaCell Therapeutics announces that it has recruited two additional clinical sites for screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT, with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat. The additional clinical sites include the following: Atlantic Health System, Morristown, New Jersey, and Tranquil Clinical Research, Webster, Texas. BriaCell's clinical sites work closely with Cancer Insight, LLC to manage the clinical and regulatory aspects of the Phase I/IIa clinical trial in advanced breast cancer on behalf of BriaCell. The following clinical sites are now open and actively enrolling patients: Atlantic Health System, Morristown, New Jersey; Tranquil Clinical and Research, Webster, Texas; Mary Crowley Cancer Research center, Dallas, Texas; St. Joseph Health-Sonoma County, Santa Rosa, California; Cancer Center of Kansas, Wichita, Kansas.

08:15 EST Enphase Energy expands Enphase Installer Network in Victoria - Enphase Energy announced steady growth in its Enphase Installer Network in Victoria, Australia as a result of market-leading partner support, state-run initiatives, and growing homeowner demand for safer, smarter, and more reliable solar systems. Victoria's commitment to solar energy is spearheaded by the Solar Homes Program, which is driven by Solar Victoria, the only state body in the country specifically formed to promote solar energy growth. Since August 2018, the Program has supported solar installation in more than 176,000 Victorian homes and has targeted over 700,000 solar homes in the state by 2028.

08:13 EST Pliant announces data from expanded Phase 1b BAL trial of PLN-74809 - Pliant Therapeutics announceddata from its expanded PLN-74809 Phase 1b proof-of-mechanism trial. PLN-74809 demonstrated clear evidence of on-target biological activity in the lungs of healthy participants. Results showed that PLN-74809 inhibited TGF-beta activation on Day 7 by up to 92% and 76% at 6- and 24-hours, respectively, following dosing. TGF-beta has been shown to be a key mediator of the fibrosis pathway in idiopathic pulmonary fibrosis. The randomized, double-blind, placebo-controlled Phase 1b trial evaluated PLN-74809's ability to suppress TGF-beta after 7 days of dosing in 36 healthy volunteers. The trial was conducted in two parts. Part 1 evaluated PLN-74809 at doses of 80 mg and 160 mg once-daily versus placebo and Part 2 evaluated PLN-74809 at a dose of 320 mg once-daily versus placebo. In addition to safety and pharmacokinetics, the trial evaluated PLN-74809's ability to suppress TGF-beta activation in the lungs of healthy volunteers as measured through relative pSmad2 levels in alveolar macrophages collected through bronchioalveolar lavage at 6 hours and 24 hours after the last dose. pSmad2 is a marker of TGF-beta activation. This trial further defines the relationship between plasma exposure of PLN-74809 and TGF-beta inhibition in the lung and will guide dose selection in future trials. All PLN-74809 treatment groups across Part 1 and Part 2 showed pSmad2 suppression relative to placebo at 6 hours and 24 hours. PLN-74809 dosed at 80 mg once-daily demonstrated mean pSmad2 reductions of 41% and 37% from baseline at 6 and 24 hours, respectively, with up to 76% reduction seen at 24 hours. PLN-74809 dosed at 160 mg once-daily demonstrated pSmad2 reductions of 58% and 53% from baseline at 6 and 24 hours, respectively, with up to 92% reduction seen at 6 hours. Statistical significance was achieved at 24 hours for both the 80 mg and 160 mg doses when compared to placebo. Both the 80 mg and the 160 mg dose cohorts demonstrated exposures above the 50% target inhibitory concentration of alphavbeta6 for 24 hours after dosing. PLN-74809 dosed at 320 mg once-daily demonstrated a mean pSmad2 reduction of 46% from baseline at 6 hours and a mean increase of 16% from baseline at 24 hours. The placebo group experienced a mean pSmad2 reduction of 8% from baseline at 6 hours and a mean increase of 151% from baseline at 24 hours. At both timepoints in the PLN-74809 arm, pSmad2 levels decreased relative to placebo. The Part 2 treated group showed exposures above IC50 of alphavbeta6 for 24 hours after dosing. On Day 7 at 24 hours post dose, the placebo groups in both Part 1 and Part 2 showed mean pSmad2 increases of 74% and 151%, respectively. These increases in pSmad2 may have been associated with the 6 hour BAL procedure. All PLN-74809 treatment groups showed pSmad2 suppression relative to placebo at 24 hours, suggesting that PLN-74809 treatment was able to inhibit TGF-beta activation triggered by BAL procedures. Acute phase response following BAL procedures has been previously described in healthy volunteers and patients. PLN-74809 was well-tolerated with mostly mild adverse events, and no severe adverse events. There was no dose relationship associated with adverse events, no serious adverse events and no treatment discontinuations due to adverse events.

08:11 EST Sharps Compliance appoints Eric Bauer as EVP, CFO - Sharps Compliance announced that it has expanded its leadership team with the appointment of Eric Bauer as Executive Vice President & Chief Financial Officer. In his new role, Mr. Bauer will oversee all aspects of Sharps' finance and accounting organization and play a key role in developing and implementing the Company's strategic initiatives and mergers and acquisitions efforts. Diana P. Diaz continues with the Company as Vice President and Chief Accounting Officer. Mr. Bauer is a highly experienced financial and investment banking professional who most recently served as Executive Vice President and Chief Financial Officer of Nuverra Environmental Solutions.

08:10 EST Central European Equity provides update on Russia - In light of current events in Ukraine, The Central and Eastern Europe Fund provided the following update: "Russia's recent military interventions in Ukraine have led to new sanctions being imposed by the United States, the European Union, the United Kingdom and other countries against Russia and certain Russian companies, and management believes that the ongoing military intervention by Russia in Ukraine may lead to further sanctions. Recent events, including the announcements of sanctions, have negatively affected the value of many of the Fund's portfolio investments, particularly its Russian investments (some of which are in companies affected by the sanctions), and may continue to do so. As of January 31, 2022, approximately 71.2% of the Fund's assets were invested in Russian securities. The Fund has not invested in securities of companies in Ukraine in recent years. The Fund intends to comply with all applicable sanctions. None of the sanctions that have been announced to date affect the Fund's ability to buy or sell securities of companies currently owned by the Fund in the secondary market, but that could change in the future. The newly imposed sanctions and any potential additional sanctions may adversely affect Russian individuals, issuers, and the Russian economy. Such sanctions may adversely affect not only the Russian economy, but also the economies of many countries in Europe, including Central and Eastern Europe. Russia's military incursions and the resulting sanctions could also adversely affect global energy, financial, agricultural, metals and other markets and thus could affect the value of the Fund's investments, even beyond any direct exposure the Fund may have to Russian issuers or the adjoining geographic regions. In short, the continuation of current sanctions on Russia or the imposition of additional sanctions may continue to materially adversely affect the value and liquidity of the Fund's portfolio and may make it more difficult for the Fund to value some of its portfolio securities. It is possible that sanctions or retaliatory measures may result in the freeze of all, or a portion of the Russian assets held by the Fund. The severity and duration of Russia's military actions, resulting sanctions and resulting market disruptions are impossible to predict, but they could be substantial."

08:10 EST Medtronic announces launch of NuVent Eustachian tube dilation balloon - Medtronic announced the launch of the NuVent Eustachian tube dilation balloon, which has been cleared by the U.S. Food and Drug Administration, FDA, for the treatment of chronic, obstructive Eustachian Tube Dysfunction. The NuVent balloon enables surgeons to deliver treatment in an outpatient or office setting. It features a flexible balloon section that allows customized placement based on patient anatomy.

08:09 EST Bridge Investment launches $75M senior housing program - Bridge Investment announced that it has launched a $75M program to acquire, develop, and operate needs-based senior housing assets within the United States. As part of the venture, StepStone Real Estate co-invested in an existing portfolio managed by Bridge and intends to help build the platform by co-investing in other senior housing assets identified by Bridge in the future.

08:08 EST Bionano Genomics announces launch of RUGD strategic initiative - Bionano Genomics announced the launch of its rare undiagnosed genetic disease strategic initiative in recognition of Rare Disease Day. There are many different causes of rare disease, but most are genetic and believed to be directly caused by changes in genes or chromosomes. In some cases, genetic changes that cause disease are passed from one generation to the next. In other cases, they occur randomly in a person who is the first in their family to be diagnosed. Karyotyping, fluorescent in situ hybridization, chromosomal microarray, targeted next-generation sequencing and whole genome sequencing are broadly used during the diagnostic odysseys associated with rare diseases and yet more than 50% of patients on average are left undiagnosed. The patients are left on a frustrating and stressful RUGD odysseys without answers. A major part of the solution is genome testing and research. Bionano offers a suite of solutions with OGM systems, genome analysis software and testing and laboratory services that may provide valuable answers for RUGD research. Today, Bionano is launching its RUGD initiative in an effort to help elevate the level of focus and dedication in translational and clinical research. Bionano's RUGD initiative will include Bionano's suite of product offerings, support for educational awareness, working towards development of research grants in this area and supporting professional societies with a shared mission of improving RUGD patient care and management, such as the American College of Medical Genetics and Genomics. As part of Bionano's RUGD initiative, Bionano has committed to provide three years of financial support for the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program in genetics and genomics. The Next Generation Fellowship & Residency Training Awards Program Attracting talented medical professionals to the genetics and genomics workforce is a core objective of the ACMGFis focused on expanding the clinician workforce pipeline by attracting excellent physicians and PhD laboratorians to genetic and genomic medicine. Bionano's three years of financial support in this program is expected to play a significant role in the ACMGF's work to add more experts to the field of RUGD research and expand the reach of genetic and genomic medicine.

08:07 EST MedMen to sell Florida assets to Green Sentry for $83M - MedMen announced plans to sell its Florida assets to Florida-based private company Green Sentry for $83M. The cash deal includes the sale of substantially all of MedMen's Florida-based assets, including its license, dispensaries, inventory and cultivation operations. Additionally, the company agreed to license its trademarks in the state for a two-year period, subject to termination rights, for a quarterly revenue-based fee. The transaction is subject to customary closing conditions, including applicable regulatory approvals. The deal is expected to close in late April or early May, pending the receipt of all required contractual consents and governmental approvals including the requisite change of ownership approval from the Florida Office of Medical Marijuana Use.

08:05 EST Seelos announces dosing of first patient in Phase II/III trial of SLS-005 - Seelos Therapeutics announced the dosing of the first participants in its registrational Phase II/III trial studying the investigational treatment SLS-005 for the treatment of amyotrophic lateral sclerosis on the HEALEY ALS Platform Trial. "Initiating this trial is a major achievement for Seelos and we are honored to be part of the HEALEY ALS Platform Trial. We look forward to offering this investigational therapy to people suffering with this debilitating disease," said Raj Mehra Ph.D., Chairman and CEO of Seelos. Seelos' Phase II/III trial plans to enroll 160 participants with either familial or sporadic ALS in a double-blind placebo-controlled trial. Participants will be randomized 3:1 and studied with a primary endpoint measuring change from baseline on Revised Amyotrophic Lateral Sclerosis Functional Rating Scale score at 24 weeks. Secondary endpoints will also be measured at 24 weeks, including change from baseline in slow vital capacity, muscle strength, quality of life measurements as well as additional signs of disease progression.

08:05 EST Clever Leaves enters $7.8M agreement with Australian Natural Therapeutics - Clever Leaves Holdings announces a four-year take or pay supply agreement with a leading Australian medicinal cannabis company, Australian Natural Therapeutics Group, to supply CBD isolate and GMP certified THC crude oil from its operation in Colombia and THC dried flower from its GACP- certified operation in Portugal. Over the term of the agreement, ANTG has committed to purchasing a minimum of US$7.8M worth of product, with the next shipment planned for March 2022. This marks the largest supply agreement Clever Leaves has signed with an Australian cannabis company, assisting the company's growth as an emerging global leader in medical cannabis supply. ANTG will utilize Clever Leaves' products to produce locally manufactured prescription medications certified to global standards, including the Australian Good Manufacturing Practice and Good Agricultural and Collection Practices. ANTG will also use Clever Leaves' products for research and development purposes.

08:03 EST Conformis announces publication on implants in retrospective study - Conformis announced results of a published retrospective study of patients showing the superiority of Conformis' implants in several key measures of clinical success and patient satisfaction. According to the study published in The Journal of Bone & Joint Surgery Reviews, patients who had undergone bilateral total knee arthroplasty preferred their Conformis fully personalized knee compared to their bilateral off-the-shelf knee at a rate of more than 10 to 1. The study surveyed 47 TKA patients who had a fully personalized Conformis implant in one knee after previously receiving a competitive off-the-shelf implant in their other knee. The study found that 72.3 percent of the patients studied preferred their fully personalized Conformis knee replacement, compared to 6.4 percent of patients who preferred their traditional off-the-shelf implant. The remaining 21.3 percent reported no perceived difference between the two knee implants. The study, believed to be the first ever to directly examine patient-reported outcomes comparing fully personalized and traditional off-the-shelf implants in the same patient as a control, underscores the higher levels of satisfaction and lower levels of pain and joint awareness associated with fully personalized implants. The patients reported less pain, better perceived mobility and a more "normal" feeling in the fully personalized Conformis implant.

08:01 EST Verizon Business appoints Maggie Hallback as SVP, Verizon Public Sector - Verizon Business appointed Maggie Hallbach to the role of senior vice president for Verizon Public Sector. She will lead the team that serves the company's federal, state, local, education and Verizon Frontline public safety customers. Over her 25 years at Verizon, Hallbach served in a variety of executive and leadership roles, most recently as Verizon Public Sector's vice president of business development and strategic sales, where she was focused on developing, designing and capturing strategic opportunities. Hallbach also led the team responsible for strategic sales initiatives, including the alignment of sales priorities to the overall Verizon Public Sector strategy.

07:57 EST Tinley Beverage Company commences Canadian production - The Tinley Beverage Company is pleased to provide US and Canadian corporate updates and to announce the closing of a second tranche of a private placement. Long Beach Facility: Can Line Set to Manufacture Client Product Week of March 7, 2022: The Company is pleased to announce that client-supplied materials required for production on the can line at Tinley's Long Beach Facility that had been delayed by supply chain issues are now expected to be received on site over the next week. The Company confirms that Lakewood Libations Inc. has been able to schedule the first commercial manufacturing run on the recently completed Codi can line, now expected to take place during the week of March 7, 2022. The Company is delighted to report that the inaugural Canadian production of its Tinleys '27TM Smooth Coconut, the Canadian version of California's Emerald Cup-award winning Tinley'sTM '27 Coconut Cask, is expected to be completed this week at its Ontario licensed contract manufacturer. These products are expected to be delivered to the Ontario Cannabis Store warehouse mid-March 2022 and will be available for Ontario dispensaries in April 2022. Production of Tinleys Classics Mystic Dove, the Canadian version of its Tinley's Tonics La Paloma Mystic Dove, has been delayed by recent border closures impacting the timing of ingredient delivery to the British Columbia licensed contract manufacturer. Production is now scheduled for March 2022. Consequently, the OCS has agreed to defer the launch of this SKU to the second phase of Spring 2022 product releases, making Mystic Dove available to Ontario dispensaries in May 2022. The Company continues to collaborate with its licensed contract manufacturers and sales agents to accommodate various provincial boards' presentation requests and 2022 listing timeframes. Updates on the Alberta Gaming and Liquor Commission decisions for April 2022 listing are expected late in March 2022. The Company continues to work towards late Spring 2022 listings of Tinley's Canadian products with the British Columbia Liquor Distribution Branch. Tinley's will provide ongoing updates to shareholders on the currently scheduled production and release dates, and on progress towards additional distribution across Canada. The Company is pleased to announce the closing of the second tranche of a non-brokered private placement of 3,450,000 of the Company for gross proceeds of C$517,500. Each Unit is comprised of one common share in the capital of Tinley's and one common share purchase warrant. Each Warrant is exercisable into one Common Share at a price of C$0.20 for a period of 24 months following the date of issuance. In consideration for the services of certain eligible finders who introduced subscribers under the Private Placement to Tinley's, the Company issued an aggregate of 108,000 compensation options to acquire 108,000 Units at a price of $0.15 per Unit and paid aggregate cash commissions of $13,800 to such finders. The net proceeds from the Private Placement will be used for working capital, capital expenditures, marketing, establishing new business lines and exploring potentially accretive transactions, including potential mergers and acquisitions. The Units, Common Shares, Compensation Options, Warrants and Warrant Shares are subject to a statutory hold period of four months and a day from the date of closing.

07:54 EST Humacyte announces publication of long-term data from Phase 2 trial of HAV - Humacyte announced that five-year data from a Phase 2 clinical trial of patients receiving the investigational Human Acellular Vessel for arteriovenous access in hemodialysis have been published in the European Journal of Vascular and Endovascular Surgery companion journal EJVES Vascular Forum. The manuscript, entitled, "Five-year outcome in patients with end-stage renal disease who received the bioengineered human acellular vessel for dialysis access," reports the durable long-term use and ongoing clinical function of the HAV in patients with end-stage renal disease who are undergoing hemodialysis. In the Phase 2 long-term follow-up data, the HAV was observed to provide routine and functional hemodialysis access for patients with end-stage renal disease who require dialysis three times a week. At month 60, patency allowing for reliable dialysis access cannulation was estimated at 58.2% of evaluable patients after censoring for deaths and withdrawals. While there was no comparator in this Phase 2 trial, historical reports of arteriovenous fistula, currently the most prevalent method of providing hemodialysis access, indicate an approximately 30% functional patency of evaluable patients at five years1. In addition, no infections of the HAV were reported during the five-year follow-up period, with the HAV being well tolerated and non-immunogenic. As a follow-up to the Phase 2 trial described in the publication, the Company is currently conducting a Phase 3 trial in up to 240 dialysis patients. The Phase 3 trial is a prospective, multi-center, open-label, randomized, two-arm comparative trial designed to assess the usability of the HAV for dialysis at six and 12 months as a comparison to autogenous fistulas. As of December 31, 2021, 207 patients had been enrolled in the Phase 3 trial. The HAV is an investigational product candidate and is not currently approved for sale by the FDA or any international regulatory authority. The prospective Phase 2 trial evaluated the HAV in 40 adult patients with end-stage renal disease undergoing hemodialysis at three sites in Poland. Of those 40 patients, 29 completed the originally specified 24-month Phase 2 trial with patent HAVs and provided consent to be followed for HAV conduit status every three months thereafter through at least five years. Secondary patency was 58.2% at five years, after censoring for deaths and withdrawals. Long-term explant samples showed progressive host-cell remodeling of the HAV, including an adventitial layer with neovascularization and recellularized medial layer that were observed in histological imaging, further strengthening the hypothesis that the HAV may regenerate into a living vascular tissue. In the five years after HAV implantation, no infections of the HAV were noted and no clinical evidence of immunological rejection was observed.

07:48 EST InflaRx provides update on development plans for vilobelimab - InflaRx reported that the Company has received an advice letter from the U.S. Food and Drug Administration related to its Phase III program with vilobelimab for the treatment of hidradenitis suppurativa. The feedback indicates that the FDA recommends using the Hidradenitis Suppurativa Clinical Response Score as the primary endpoint in the Phase III trial. The FDA advice was provided nearly three months after the Company's protocol submission and contrasts with the FDA advice provided to the Company in a Type A meeting held in Q3 2021. In the minutes of that meeting, FDA provided advice on how to implement, name and validate the meaningfulness of the modified HiSCR, a new primary endpoint suggested by the Company, that would measure the reduction of all three types of inflammatory lesions in HS - inflammatory nodules, abscesses and draining tunnels. A reduction in draining tunnels is not captured by the HiSCR. Within the Type A written response, FDA did not recommend the traditional HiSCR as the primary endpoint measure. Following the advice received in the Type A meeting, earlier this year, InflaRx announced the initiation of a Phase III trial, designed to study patients with moderate to severe HS disease suffering from actively draining tunnels. Given the unexpected details of the feedback from the FDA, InflaRx will pause activities related to the Phase III trial. The Company will seek to clarify the advice received and determine next steps, which will be communicated accordingly. The FDA has not issued a clinical hold. As previously announced, InflaRx completed a Type A meeting with the FDA in Q3 2021 to align on the Phase III HS study design. In this meeting, FDA and InflaRx discussed together a new primary efficacy endpoint for a pivotal study program that focuses on patients with active draining tunnels and includes measuring the reduction of all three types of inflammatory lesions. InflaRx incorporated the FDA's input and submitted the Phase III protocol to the Agency in late November 2021. The FDA had no comments during the 30-day nor the 60-day review period. In Q1 2022, InflaRx determined it was appropriate to begin study activities, as the Company did not expect any critical protocol review issues to be pending with FDA.

07:46 EST Singular Genomics partners with Qiagen for QIAseq Kits - Singular Genomics Systems announced a partnership with QIAGEN to validate its QIAseq kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform.

07:45 EST Applied Therapeutics supports annual Rare Disease Day - Applied Therapeutics is recognizing the 15th Annual Rare Disease Day to help elevate awareness of rare diseases and call attention to the unique challenges facing people with rare diseases. Applied Therapeutics is proud to support Rare Disease Day events across the U.S., including participating in the 5th Annual GLOW for Galactosemia Event in Knoxville, Tennessee, and virtually supporting GLOW teams across the country as they raise awareness of Galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize the sugar galactose, which is found in foods and is also synthesized by the body. The company is collaborating with advocacy partners on a wide range of Galactosemia initiatives throughout the year, including Race 4 Jase and Fore Joey's Cause. Applied Therapeutics is also partnering with the Charcot-Marie-Tooth Foundation and the Hereditary Neuropathy Foundation to raise awareness of SORD Deficiency, a rare disease which results in a progressive, debilitating hereditary neuropathy.

07:44 EST Adamis announces study of Tempol surpasses enrollment expectations - Adamis Pharmaceuticals announced that due to the acceleration of patient enrollment in the double-blind placebo controlled Phase 2/3 trial for Tempol for the treatment of COVID-19, an ad-hoc meeting of the Data Safety Monitoring Board was held to evaluate interim clinical and safety data for the trial. The DSMB is composed of subject matter experts and can unblind the data to determine the treatment effects of the subjects in the trial. Based on an analysis of the data, the DSMB determined that the study can continue, as there were no safety or clinical concerns identified. The data from the first 50 subjects will be reviewed again in March when the DSMB will examine additional clinical and safety data as part of the first planned interim analysis. The Company previously announced the results of a published study in collaboration with Stanford University researchers, suggesting that Tempol has strong, broad in-vitro anti-cytokine activity. In addition, the Company previously announced that in an animal SARS-COV2 challenge model, a decrease in inflammation was noted in the lungs of animals given Tempol compared to control animals. Additionally, independent researchers from the National Institutes of Health recently highlighted Tempol as a potential home antiviral treatment for COVID-19. In contrast to two recently Emergency Use Authorization approved oral antivirals for the treatment of COVID-19, Adamis Pharmaceuticals believes that Tempol addresses an unmet medical need because of its unique multiple mechanisms of action and well tolerated safety profile shown in previous preclinical studies.

07:43 EST Renewable Energy trading resumes

07:43 EST QIWI trading halted, news pending

07:43 EST HeadHunter Group PLC (ADS) trading halted, news pending

07:43 EST Panasonic to begin mass producing new Tesla battery by in FY ending Mar. 2024 - Panasonic announced that its Energy Company will establish a production facility at its Wakayama Factory in western Japan to manufacture new, "4680" lithium-ion batteries for electric vehicles in order to expand its business globally. To contribute to the rapid adoption of EVs, Panasonic has been working to enhance its line-up of automotive lithium-ion batteries. Currently, Panasonic is developing a new high-capacity lithium-ion battery, the "4680", in multiple locations within Japan. The company will progressively develop production capabilities in preparation for the full rollout. Along with structural improvements, two additional production lines as well as utility facilities will be established at the Wakayama Factory, and productivity verification and mass production are set to begin in the fiscal year ending in March 2024.

07:42 EST Accuray announces NICE endorses radiosurgery treatments for TN - Accuray announced that the National Institute for Health and Care Excellence, NICE, has endorsed the use of radiosurgery for trigeminal neuralgia, TN, strengthening the evidence for the company to market its CyberKnife Treatment Delivery System for this indication in the United Kingdom. The endorsement increases access to a system used worldwide to provide a high-precision radiosurgery treatment alternative to surgery for the management of this chronic and potentially debilitating neurologic condition. "Trigeminal neuralgia has the potential to significantly impact a person's quality of life if not appropriately managed, resulting in issues ranging from weight loss to isolation and depression. I'm honored to share this positive CyberKnife System news and to lead an organization whose radiosurgery device can make such a meaningful difference in the lives of these patients," said Suzanne Winter, president of Accuray.

07:40 EST Victoria Gold announces Raven drill results - Victoria Gold is pleased to provide assay results received to date from the 2021 Dublin Gulch exploration program's Raven diamond drillholes. Raven is one of several priority on/near-surface gold targets within the Dublin Gulch Gold Camp and was the primary focus of 2021 Dublin Gulch exploration activities. During the 2021 season, 20,000 meters (m) of diamond drilling were completed across the claim package; including 33 drillholes for 8,063 m at Raven. Highlighted assay results from 19 Raven holes follow: 1.25 g/t Au over 70.0 m from 245.0m in NG21-067C; 1.67 g/t Au over 13.5m from 97.7m in NG21-050C; 1.01 g/t Au over 21.1m from 155.8m in NG21-055C; 1.74 g/t Au over 15.1m from 92.4m in NG21-061C; 1.49 g/t Au over 21m of from 286.7m in NG21-062C. The 2021 Raven exploration program was designed to build upon a previously defined 750m strike length from fence-based diamond drilling, surface trenches and additional detailed structural analysis and mapping. The 2021 program successfully doubled the strike length of Raven to ~1.3 km, particularly to the west in an area covered by overlying metasedimentary lithologies. The Company is targeting an inaugural mineral resource estimate for Raven this year. "Raven continues to produce high grade gold intervals with continuity across a greatly expanded 1.3 km strike length.", commented John McConnell, President and CEO of Victoria, "Importantly, it is our intention to fast track Raven development with a focused 2 kilometer drilling program in 2022."

07:37 EST Orca Energy Group announces independent reserves evaluation - Orca Energy Group Inc announces the approval of its Independent Reserves Evaluation as at December 31, 2021. The Company's conventional natural gas reserves as at December 31, 2021 for the period to the end of the primary term of the production sharing agreement with the Tanzanian Petroleum Development Corporation have been evaluated by independent petroleum engineering consultants McDaniel & Associates Consultants in accordance with the definitions, standards and procedures contained in the Canadian Oil and Gas Evaluation Handbookand National Instrument 51-101 - Standards of Disclosure for Oil and Gas Activities. The Songo Songo PSA expires upon the expiry of TPDC's Songo Songo licence in respect of the Songo Songo gas field in October 2026. The preparation date of the independent reserves evaluation prepared by McDaniel is February 24, 2022 and the effective date of the evaluation is December 31, 2021. All the Company's reserves are located in Tanzania. Reserves included herein are stated on a Company gross reserves basis unless noted otherwise. Company gross reserves are the total of the Company's working interest share in reserves before deduction of royalties owned by others and without including any royalty interests of the Company, and are based on the Company's 92.07 percent ownership interest in the reserves following the transaction with Swala Oil & Gas. Total Proved Gross Company conventional natural gas reserves at year ended December 31, 2021, were 160 billion standard cubic feet ("Bcf"). After adjustment for the Company's share of gas produced in 2021, this represents an 11 %, or 21 Bcf decrease from the year end 2020. Total Proved plus Probable Gross Company conventional natural gas reserves at year ended December 31, 2021, were 188 Bcf. After adjustment for the Company's share of gas produced in 2021, this represents a 9%, or 22 Bcf decrease from the year end 2020. Net Present Value of 1P future net revenue discounted at 10% was $177.8 million at year end 2021, compared to $216.4 million at year end 2020, representing an 18% decrease. Net Present Value of 2P future net revenue discounted at 10% was $209.9 million at year end 2021, compared to $241.3 million at year end 2020, representing a 13% decrease. The reduction in Gross Company 1P reserves from year end 2020 to year end 2021 are attributed to lower forecasted Company conventional natural gas sales, which will be classified as Additional Gas, as defined in the Songo Songo PSA to the end of the current Songo Songo Licence term. While actual gas demand is forecasted to increase, the startup of several new gas demand projects shifted during the past year, in part due to COVID-19 pandemic related impacts on investment, construction and supply chains. The reduction in net present values of future net revenue was primarily attributed to lower reserves at year end 2021 associated with the reduced number of years remaining on the Songo Songo Licence.

07:35 EST W.P. Carey announces proposed merger with CPA:18 in $2.7B transaction - W. P. Carey announced that its Board of Directors has unanimously approved entry into a definitive merger agreement pursuant to which Corporate Property Associates 18 - Global Incorporated, CPA:18, will be acquired by W. P. Carey in a transaction valued at approximately $2.7B, including the assumption of debt. The transaction has also been approved by CPA:18's Board of Directors upon the unanimous recommendation of a Special Committee of CPA:18's independent directors. Subject to the terms and conditions of the merger agreement, CPA:18 stockholders will be entitled to receive a fixed exchange ratio of 0.0978 of a share of W. P. Carey common stock plus $3.00 of cash for each share of CPA:18 common stock held by them, representing total consideration with an initial implied value of $10.45 per share. "This acquisition presents a unique and compelling opportunity to acquire assets we know extremely well that are aligned with our current portfolio, in a transaction that's immediately accretive to our Real Estate AFFO per share," said Jason Fox, W. P. Carey's CEO. "We expect this accretion to largely replace the income we generated from managing CPA:18 with higher-quality lease revenues - and we see the potential for additional upside. Furthermore, it will essentially conclude our exit from Investment Management, further simplifying our business and enhancing our scale."

07:32 EST MacroGenics promotes Eric Riser to COO - MacroGenics announced that it has promoted Eric Risser to Chief Operating Officer, as of February 22. Mr. Risser joined MacroGenics in 2009 and has played an instrumental leadership role in sourcing, structuring and negotiating the company's collaboration partnerships and has been responsible for the Company's alliance and program management and new product planning functions.

07:32 EST Telesat, Liquid Intelligent Technologies sign agreement for Telesat Lightspeed - Telesat and Liquid Intelligent Technologies announced a strategic cooperation agreement to explore reciprocal go-to-market strategies to bring Telesat Lightspeed Low Earth Orbit satellite services to Africa. As part of the agreement, the companies will closely collaborate on the commercial and technical aspects of integrating the Telesat Lightspeed enterprise-grade, high-throughput, low-latency satellite network with Liquid's global value-added services network. This integration can enable the expansion of Liquid's enterprise portfolio offerings, including next-generation cloud services, managed security services, business Wi-Fi and data center connectivity. At the same time, Telesat will explore combining Liquid's landing stations, Points of Presences (PoPs), site hosting, management services, and fibre network as part of its global terrestrial infrastructure that seamlessly integrates with the Telesat Lightspeed satellite network.

07:29 EST Solaris Resources reports assay results from Warintza Project - Solaris Resources is pleased to report assay results from a series of additional holes from mineral resource growth drilling at its Warintza Project in southeastern Ecuador. Highlights: Additional holes have enlarged the drill defined envelope of mineralization at Warintza Central, with the highest-grade intersection reported to date building on an emerging near surface, high-grade extension to the northeast that remains open, as well as to the south and southeast. Drilling Returns Highest Grades Reported to Date in Emerging Northeast Extension that Remains Open: SLS-42 was collared at the northeastern limit of the grid and drilled northeast into an entirely open volume, returning 740m of 0.60% CuEq from 52m depth within a broader interval of 906m of 0.53% CuEq, extending mineralization in this direction where it remains open. SLS-49 was drilled southeast from the same platform and returned 396m of 0.70% CuEq within a broader interval of 817m of 0.60% CuEq from 50m depth, tying the northeast extension to the overlap between Warintza Central and East. SLS-48, was collared in an undrilled area ~200m west of SLS-49 and drilled south, returning 100m of 1.64% CuEq from 50m depth, the highest-grade mineralization reported to date, within a broader interval of 852m of 0.56% CuEq, extending the near surface high-grade mineralization to the west in that area. These results expand Warintza Central by building on an emerging area of near surface, high-grade mineralization; follow-up drilling will pursue further growth by targeting the open areas to the north and northwest, with an additional platform being constructed to pursue further step-outs to the northeast. Drilling Extends Mineralization to Southeast that Remains Open: SLS-45 was collared on the eastern side of the grid and drilled southeast into an entirely open volume, returning 236m of 0.56% CuEq from 44m depth within a broader interval of 564m of 0.41% CuEq, extending mineralization to the southeast where it remains open. SLS-46 was collared from a southeastern platform and drilled southeast into a partially open volume, returning 168m of 0.69% CuEq from 48m depth within a broader interval of 632m of 0.31% CuEq, extending mineralization in this direction where it remains open SLS-47 was collared in the middle of the grid and drilled southeast to infill this area, returning 446m of 0.70% CuEq from 48m depth within a broader interval of 811m of 0.51% CuEq, with mineralization remaining open to the south To date, 58 holes have been completed at Warintza Central with assays reported for 49 of these. Updated Warintza Central Mineral Resource expected to be issued in late Q1 2022 / early Q2 2022. Mr. Jorge Fierro, Vice President, Exploration, commented: "The initial resource growth drilling program for Warintza Central has been completed which will inform the updated mineral resource estimate. With this intensive program behind us, the focus of ongoing drilling has turned to pursuing the further extensions of near-surface, high-grade mineralization which remain open, with additional platforms allowing for more aggressive step-outs under construction."

07:27 EST Parsons awarded $104M contract by Intelligence Community - Parsons Corporation was awarded a $104 million, single-award five-year contract by the Intelligence Community. Parsons will provide vulnerability research, reverse engineering, software development, and engineering support services to the IC. The company develops tailored cyber and intelligence solutions that accelerate mission success across the all-domain environment and provides resources for customers to solve complex security issues while enabling rapid response to existing and emerging, non-traditional threats.

07:27 EST First Bancshares qualifies for OTCQX Best Market - OTC Markets Group announced First Bancshares, the holding company for Stockmens Bank, has qualified to trade on the OTCQX Best Market. First Bancshares, Inc. upgraded to OTCQX from the Pink market.

07:25 EST InspireMD announces inclusion of CGuard Carotid Stent in CREST-2 trial - InspireMD announced its CGuard Carotid Stent, utilizing its proprietary MicroNet mesh, will be included as a device option for stenting in the CREST-2 Trial. Following the approval of the Carotid Revascularization Endarterectomy or Stenting Trial Investigational Device Exemption supplement application from the U.S. Food and Drug Administration last week, InspireMD will be evaluating strategic sites to enable expediated access. The study first enrolled patients in 2014, as two parallel multi-center randomized, observer-blinded endpoint clinical trials with the purpose of being to determine the best way to prevent strokes in patients with high grade carotid stenosis but no stroke symptoms related to that blockage. The trial will enroll an estimated 2,480 participants which will remain in the study for 4 years following the start of intervention.

07:24 EST Tonix Pharmaceuticals announces research agreement with Inserm - Tonix Pharmaceuticals Holding announced that it has entered into a sponsored research agreement with Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm and Aix-Marseille Universite to study oxytocin in the genetically engineered mouse model of Prader-Willi syndrome, a rare genetic disorder that causes distinct, but related pathological eating disorders in adults and newborns. In adults, Prader-Willi causes hyperphagia, or pathological over-eating, which leads to obesity and other complications associated with significant mortality. In newborns, Prader-Willi causes a deficiency in suckling, which has been shown to be normalized by oxytocin treatment. Tonix is developing TNX-2900 for the treatment of Prader-Willi Syndrome in adults and adolescents. A related intranasal potentiated oxytocin product candidate, TNX-1900*, is under development for the treatment of chronic migraine and is expected to enter a Phase 2 clinical trial for the prevention of migraine headache in chronic migraineurs in the second half of 2022. The proposed research, directed by Professor Francoise Muscatelli at the Institut de Neurobiologie de la Mediterranee, will involve in vitro and in vivo studies designed to characterize the mechanism by which oxytocin normalizes the suckling and maturation of feeding behavior during infancy in mice that have been genetically modified to recapitulate part of the genetic alterations underlying Prader-Willi in humans. The results of this work are expected to increase the understanding of the mechanism by which oxytocin regulates feeding behavior in a mouse model of Prader-Willi. In 2021, Tonix licensed technology for treating Prader-Willi syndrome from Inserm, Aix Marseille Universite and Centre Hospitalier Universitaire of Toulouse. The patents covering the technology are expected to provide market exclusivity for the co-licensees in the U.S. and Europe through 2031, which exclusivity could be extended after marketing authorization by a Supplemental Protection Certificate in Europe or a Patent Term Extension in the U.S., independent of other Tonix-held patents covering the formulation and oxytocin potentiation technologies for intranasal administration. Additionally, Tonix has submitted an application to the FDA for orphan drug designation.

07:22 EST Boralex projects selected in latest call for tenders in France - Boralex is announcing that three of its wind projects totalling 61.9 MW have been selected in the latest CRE 09 onshore wind call for tenders conducted by the Ministry for the Ecological Transition in France. Boralex has already secured 322 MW of new projects as part of the nine wind power tenders conducted by the Ministry for the Ecological Transition in France. This puts Boralex in the top three of companies that have won the most MW since the beginning of onshore wind power tenders in France, according to an analysis conducted by the consulting and transaction firm Envinergy. The projects have received the necessary administrative authorizations and will enable Boralex to receive a feed-in premium agreement over a period of 20 years from the date of commissioning. Boralex currently has a portfolio of more than 1.5 GW in wind and solar power projects in France, at various stages of development. The Company also has 1.1 GW in wind and solar power sites operating in France and 2.5 GW around the world.

07:21 EST Zynerba announces completion of enrollment in Phase 2 trial of Zygel - Zynerba Pharmaceuticals announced the completion of enrollment for the 14-week Phase 2 INSPIRE trial of Zygel in the treatment of behavioral symptoms of 22q11.2 deletion syndrome in children and adolescents. The Company continues to expect topline data from this trial mid-year 2022. The Company has previously received orphan drug designation for Zygel in 22q from the FDA. The 14-week INSPIRE trial is an open-label, multi-dose, Phase 2 clinical trial designed to evaluate the efficacy and safety of Zygel in children and adolescents with genetically-confirmed 22q. Enrolled patients receive weight-based doses of 250 mg daily or 500 mg daily of Zygel. The efficacy assessments include the Aberrant Behavior Checklist-Community, the Anxiety, Depression and Mood Scale, the Qualitative Caregiver Reported Behavioral Problem Survey, and Clinical Global Impression - Severity and Improvement. A total of 20 patients have been enrolled in the INSPIRE trial.

07:20 EST PDC Energy sees $1.3B in 2022 free cash flows - In 2022, PDC "projects to generate approximately $1.3 billion of after-tax free cash flows with more than $800 million of total shareholder returns. Anticipated 2022 capital investments between $900 million and $1.0 billion are expected to generate total production between 225,000 and 240,000 Boe per day and between 74,000 and 81,000 Bbls of oil per day. Post-close, the Company plans to operate three Wattenberg rigs, one Delaware rig and one and a half Wattenberg completion crews, resulting in anticipated second half daily total production and daily oil production of approximately 250,000 to 260,000 Boe and 82,000 to 87,000 Bbls, respectively."

07:19 EST ALX Oncology expects cash to fund operations through mid-2024 - Cash and cash equivalents as of December 31, 2021 were $363.7 million. ALX Oncology believes its cash and cash equivalents is sufficient to fund planned operations through mid-2024.

07:16 EST Embark Technology partners with Alterra Property Group - Embark Trucks announced a strategic partnership with Alterra Property Group, one of the largest and first real estate investment companies in the US focused on industrial outdoor storage properties, to identify and launch transfer point sites across the US Sunbelt. These new transfer points will increase the reach of the Embark Coverage Map and enable new autonomous trucking lanes as Embark prepares for commercial deployment of its technology in 2024.

07:14 EST PDC Energy to acquire Great Western in $1.3B deal - PDC Energy announced it has entered into a definitive purchase agreement with Great Western Petroleum, LLC and certain sellers under which PDC will acquire Great Western in a transaction valued at approximately $1.3B, including net debt of approximately $500M. Great Western is a Denver-based DJ Basin operator owned by affiliates of EIG, TPG Energy Solutions, L.P. and The Broe Group. Under the terms of the agreement, the Acquisition will be financed through the issuance of approximately 4.0 million shares of common stock to existing Great Western shareholders and approximately $543M of cash, subject to customary post-closing adjustments. The transaction is expected to close in the second quarter of 2022 and is expected to be financed with cash on hand and borrowings under the Company's credit facility. PDC does not expect its pro forma leverage ratio to exceed 1.0x upon closing."

07:10 EST Nielsen, Experian expand agreement to enhance identity demographics - Nielsen (NLSN) and Experian (EXPGY) announced an expanded strategic initiative to enhance identity data in the United States for digital measurement of the open web. Experian marketing data assets will enhance the Nielsen Identity System by providing persistent IDs for open web measurement, increasing coverage and interoperability by supporting audience measurement across screens and devices that are consistent and comparable. "Integrating Experian marketing data assets into the Nielsen ID System will further strengthen Nielsen's ability to match person-level data to devices, increasing the scale and accuracy of demographic distribution for reported impressions for Nielsen's Audience Measurement and Outcomes products," the company said. "This expanded agreement with Experian immediately enriches Nielsen's Identity System in the US, and showcases our commitment to independent measurement and marketplace interoperability," said Mainak Mazumdar, Chief Data and Research Officer, Nielsen. "This is an important milestone as we continue to evolve our technologies and methodologies as we move toward Nielsen ONE, underpinning a strong digital measurement capability which helps with the vision of a true cross-platform that measures across all screens."

07:08 EST Main Street receives board approval to reduce asset coverage ratio to 150% - Main Street Capital announces that it has received approval from its Board of Directors to reduce its minimum asset coverage ratio to 150% from 200%. The reduction to Main Street's minimum asset coverage ratio is being made pursuant to Section 61(a)(2) of the Investment Company Act of 1940, which provides that such approval shall take effect on the one-year anniversary of the Board of Directors' approval. The Board of Directors has also approved the submission of a proposal to adopt the reduced minimum asset coverage ratio at Main Street's 2022 annual meeting of stockholders, which, if approved, would take effect the day after the meeting.

07:08 EST Spin Master renews Warner Bros consumer products global licensing agreement - Spin Master (SNMSF) announced that it has renewed its global licensing agreement with Warner Bros. (T) Consumer Products, WBCP, and DC for the iconic Batman franchise and other DC Super Heroes. Spin Master first joined forces with WBCP in 2018 as the toy licensee for DC in the action figure, playset, roleplay and vehicle categories for the period of 2019-2022 and has now extended the relationship for a four-year term beginning in 2023 through to 2026. "It's been an honour to work with Warner Bros. Consumer Products on this heroic and innovative line of action figures, vehicles and playsets, bringing the adventures and stories of Batman, DC Super Heroes and Super-Villains into fans' homes around the world," said Chris Beardall, Spin Master's President, Toys and Chief Commercial Officer. "The timing of this renewal is perfect as we head into a blockbuster year for DC, with it's incredible slate of feature films hitting the big screen in 2022 coinciding with custom toy collections for each. Our innovative approach to toy design combined with our meticulous attention to detail has helped to achieve record-setting sales for Spin Master's DC toy line."

07:06 EST Ecolab chairman Douglas Baker to retire, CEO Christophe Beck to succeed - Ecolab announced that Douglas Baker, executive chairman of the board of directors of Ecolab, has informed the company that he will step down from the board following the expiration of his current term at Ecolab's 2022 annual meeting of shareholders on May 5. Christophe Beck, president and chief executive officer, and a member of the board of directors, has been elected by the board to serve as chair, in addition to his current responsibilities, effective upon the expiration of Baker's term. Jeff Ettinger will remain lead independent director.

07:04 EST MediciNova announces publication on MN-166 - MediciNova announced that MN-166 was discussed as a potential beneficial pharmacological agent for the treatment of degenerative cervical myelopathy in Global Spine Journal.The publication entitled "Developing Novel Therapies for Degenerative Cervical Myelopathy: Opportunities from Restorative Neurobiology" and co-authored by MediciNova's collaborator, Dr. Mark Kotter, Professor, Neurosurgery Unit, Department of Clinical Neuroscience, University of Cambridge, UK, and colleagues, discussed contemporary therapies that may hold therapeutic value in three broad categories of neuroprotection, neuroregeneration, and neuromodulation. Among those reviewed, the authors discuss the attributes of MN-166 (ibudilast) that support its use in DCM. The combination of anti-inflammatory, neuroprotective, and neuroregenerative properties of MN-166 is the basis for RECEDE-Myelopathy, a Phase 3, double-blind, randomized controlled trial assessing its efficacy as an adjuvant treatment to decompressive surgery for DCM on mJOA score and neck pain. Key take-aways in the publication include: Chronic spinal cord compression due to DCM leads to ischaemia, neuroinflammation, demyelination, and neuronal loss. People with DCM often develop and then suffer from lifelong disability, with less than 5% making a full recovery despite surgical decompression. An increase in activated microglia and macrophages has been observed at the site of chronic spinal cord compression and is a source of pro-inflammatory cytokines and can lead to further cell death by necrosis and apoptosis. MN-166 has been shown to exhibit central anti-inflammatory, neuroprotective, and neurotrophic/neuroregenerative effects by inhibition of phosphodiesterase (PDE4 and PDE10) and macrophage migration inhibitory factor. This combination of effects, which leads to attenuation of glial cell activation and enhancement of neurotrophic/neuroregenerative factors, makes a compelling case to assess MN-166 for the treatment of DCM. MN-166 is the only drug currently being evaluated in Phase 3 as a regenerative medicine for the treatment of DCM.

06:59 EST Lithium Americas exploring possible separation of U.S. lithium business - Lithium Americas continues to make meaningful progress at its projects in both the United States and Argentina: United States: In addition to the draft application with the DOE, the Company received all final key state permits for Thacker Pass on February 25, 2022. Funding discussions with a variety of strategic partners are ongoing along with the completion of the feasibility study incorporating increased scale, additional processing and related infrastructure changes and the results of engineering and testing. Capital and operating cost estimates are being updated to reflect these changes, as well as to account for external factors such as inflationary pressures and supply chain considerations. Argentina: The Company's Cauchari-Olaroz lithium brine project is set to complete construction this year as the largest new battery-quality lithium carbonate brine operation to come online in over 20 years. The Cauchari-Olaroz expansion and the recently acquired Pastos Grandes lithium brine project provide further growth potential to support a regional lithium operation in northern Argentina. As Lithium Americas continues to advance its projects in both regions towards production, the Company has started the process of exploring a separation of its US and Argentina operations, through the creation of a standalone public company focused on the development of Thacker Pass. The Company is assessing available alternatives and structures to effect such separation. No final decision has been made with respect to any potential separation transaction. No assurance can be given as to whether a separation transaction will take place, the form of any such transaction or the timing of any transaction.

06:58 EST China Index Holdings appoints Richard Dai as chairman of the board - China Index Holdings announced changes in its board of directors. Vincent Tianquan Mo, the Company's founder and Chairman of the Board, has stepped down from the Board, the nominating and corporate governance committee and the compensation committee of the Board, for personal reasons, effective from February 28, 2022. Mr. Mo's resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has nominated and appointed Mr. Richard Jiangong Dai , as a director and Chairman of the Board, and chairman of both the compensation committee and the nominating and corporate governance committee of the Board, effective from February 28, 2022. Mr. Dai expressed that he would try his best to create values for the Company and the shareholders. Mr. Dai joined Fang Holdings Limited in 1999 and served multiple positions in Fang including Fang's president and chief executive officer from 1999 to 2014 and Fang's director from September 2010 to February 2016. Mr. Dai co-founded Yiyi Technology in 2015 and Xiangshui Technology in 2018 and served as chief executive officer for the two companies. Mr. Dai received a master's degree from Stanford University and a bachelor's degree from Guangxi University. Upon the effectiveness of Mr. Dai's appointment and Mr. Mo's resignation, the Board will consist of five directors, including three independent directors.

06:55 EST Evelo Biosciences announces data from follow-up of Phase 2 trial of EDP1815 - Evelo Biosciences announced data from the post-treatment follow-up of its Phase 2 trial of EDP1815 in mild and moderate psoriasis which included durable and deeper clinical responses. EDP1815 is an investigational oral biologic currently in development for the treatment of a broad range of inflammatory diseases, including clinical programs in psoriasis, atopic dermatitis, and COVID-19. The EDP1815-201 Phase 2 trial was comprised of a Part A, when patients received either EDP1815 or placebo for 16 weeks, and a Part B, when patients were followed for up to 24 weeks after they had stopped receiving EDP1815 or placebo. There were 83 patients who had received EDP1815 in Part A who entered Part B. Thirty of these 83 patients had achieved a PASI-50 or greater reduction at week 16 of Part A. Eighteen of the 30 patients remained at PASI-50 or greater at the end of Part B. Ten of the 30 patients had achieved a PASI-75 or greater at the end of Part A and 5 remained at PASI-75 or greater at the end of Part B. These durable results were achieved without any new psoriasis medication being used during this time. Nineteen of the 83 patients had achieved clear skin or nearly clear skin at the end of Part A and of these, 9 remained at PGA 0/1 at the end of Part B. Of the 30 patients who had reached a PASI-50 at the end of Part A and entered Part B, 10 had already achieved a PASI-75 response at week 16 in Part A. Of the remaining 20 patients, 9 achieved a PASI-75 or greater response during the post-treatment period. These data, combined with the durability data, suggest that longer dosing could lead to further deepening of the responses in some patients. The tolerability and safety data for EDP1815 in the trial was comparable to placebo, with the additional finding of no flare or rebound following discontinuation of therapy.

06:53 EST Genevant Sciences, Arbutus file patent infringement suit against Moderna - Genevant Sciences and Arbutus Biopharma Corporation filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of mRNA-1273, Moderna's vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. Genevant and Arbutus do not seek an injunction or otherwise to impede the sale, manufacture or distribution of mRNA-1273. Genevant is collaborating with various companies and nonprofits to develop vaccines against COVID-19 in territories around the world, including low- and middle-income countries, with the goal of eradicating COVID-19. It is well established in the scientific literature that the most significant technological hurdle to developing and deploying medicines using mRNA is engineering a safe and effective way to deliver the mRNA to human cells. Scientists at Arbutus and Genevant have spent years developing and refining lipid nanoparticle delivery technology, which has been licensed for various applications to many different third parties. Genevant and Arbutus's LNP technology relies on microscopic particles built from four carefully selected types of fat-like molecules to shelter and protect RNA molecules. With this technology, the RNA can travel through the human body to a target cell and through the target cell's membrane before releasing the RNA. Without this crucial delivery technology, the RNA would quickly degrade in the body and be ineffective. In December 2021, the United States Court of Appeals for the Federal Circuit rejected Moderna's appeal of a prior decision of the U.S. Patent Trial and Appeal Board holding all claims of the asserted '069 patent to be patentable and dismissed Moderna's appeal challenging a similar finding of patentability with respect to certain claims of the asserted '435 patent. Moderna had initiated inter partes review challenges against these patents in 2018 and 2019.

06:50 EST NovaBay to present DERMAdoctor eczema treatment on OVC - NovaBay Pharmaceuticals announces that Chief Product Officer Audrey Kunin, MD will present DERMAdoctor's problem-solving eczema treatment as a live on-air guest on the QVC network. The revolutionary Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm will be featured on "Cheers! to Shopping with Leah and Shawn" on Tuesday, March 1 at 10 p.m. Eastern time.

06:49 EST Target Hospitality CEO Brad Archer to step down - Target Hospitality announced that Brad Archer has decided to step down as president, CEO and member of the company's board of directors. As part of its succession plan, the board has formed a search committee and will engage an executive search firm to identify a successor CEO. Archer will continue to lead the company in his current position, assist with the CEO search and help onboard his successor until December 31, ensuring an orderly transition. He will also continue to work as a senior strategic advisor to the company as needed.

06:48 EST Healthcare Realty Trust, Healthcare Trust enter into $18B strategic combination - Healthcare Realty Trust Incorporated (HR) and Healthcare Trust of America, Inc. (HTA) announced that they have agreed to enter into a strategic business combination. HTA shareholders will receive a total implied value of $35.08 per share comprised of a special cash dividend of $4.82 per share and a transaction exchange ratio of 1:1 based on HR's unaffected price of $30.26 on February 24, 2022. This transaction brings together two of the largest owners of medical office buildings, creating the preeminent, pure-play medical office building REIT and positions the combined companyto create long-term shareholder value. The company will have a pro forma equity market capitalization of approximately $11.6 billion and a total enterprise value of $17.6 billion based on the implied values at market close on February 24, 2022. The company will be led by the Healthcare Realty management team, with Todd Meredith as President and CEO and Kris Douglas as Executive Vice President and CFO. Upon completion of the transaction, the new company will continue to operate with the Healthcare Realty name and trade on the NYSE under the ticker symbol HR. The company expects to realize annual run rate cost synergies of $33 - 36 million within 12 months of closing from the elimination of duplicative corporate and public company costs. At closing, each share of HR common stock will be exchanged for one share of HTA common stock, at a fixed ratio. In addition, a special cash dividend of $4.82 per share will be distributed to HTA shareholders. Taken together and based on HR's share price at the close of markets on February 24, 2022, HTA shareholders will realize an implied value of $35.08 per HTA share, representing an 18.2% premium to HTA's share price at the close of markets on February 24, 2022. This combination is structured as a reverse merger whereby Healthcare Trust of America will be the corporate successor and the company's name will continue as Healthcare Realty Trust Incorporated. Pro forma for the transaction HR and HTA shareholders will own 39% and 61% of the company, respectively. The special cash dividend of approximately $1.1 billion will be financed through joint venture transactions and asset sales. JPMorgan Chase Bank, N.A. has provided a commitment letter to Healthcare Trust of America for a $1.7 billion debt financing for the transaction upon the terms and conditions set forth in the letter. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions, including the approval of both Healthcare Realty and Healthcare Trust of America shareholders. The transaction was unanimously approved by the Board of Directors of HR and the Board of Directors of HTA.

06:47 EST BWX Technologies releases 2022 sustainability report - BWX Technologies announced the release of its 2022 Sustainability Report. The report reviews the company's environmental, social and governance achievements and describes how BWXT uses its nuclear expertise to deliver safe and effective solutions to address some of the world's most important problems in areas as diverse as global security, clean energy, environmental restoration, nuclear medicine and space exploration. "We are pleased to share our ESG commitments, accomplishments and product impacts with our stakeholders," said BWXT President and Chief Executive Officer Rex Geveden. "From providing reliable, uninterrupted and carbon-free energy to developing new, more sustainable techniques for manufacturing medical radioisotopes, we are committed to making the world a better place. Our journey ahead is exciting as we employ nuclear technologies to address some of the many challenges facing our world."

06:46 EST U.S. Steel announces pig iron investment at Gary Works - United States Steel Corporation announced that it is advancing its metallics strategy by insourcing pig iron capabilities at Gary Works. The approximately $60 million investment will produce up to 500,000 tons of pig iron annually and provide a critical raw material input for its electric arc furnaces. Once complete, the Gary pig iron production is expected to provide nearly 50% of Big River Steel's other ore-based metallics needs, contribute over $30 million of run-rate enterprise EBITDA benefits and deliver an internal rate of return in excess of 30%. The decision to self-fund pig iron production rather than contract is expected to further enhance Big River Steel's cost structure while adding value at Gary Works by driving blast furnace efficiencies without reducing Gary Works' raw steel output. The permitting process is well underway, with construction expected to commence in the first half of 2022. Pig iron production at Gary Works should begin in the first half of 2023. The company expects to maintain its previously stated 2022 capital spending budget of approximately $2.3 billion by offsetting the pig iron investment within the capital budget.

06:45 EST Q&K International announces ADS ratio change - Q&K International Group announced that it will change the ratio of the American depositary shares representing its Class A ordinary shares from one ADS representing thirty Class A ordinary share to one (1) ADS representing one hundred and fifty Class A ordinary shares. For the ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split. There will be no change to the Company's Class A ordinary shares. The effect of the ratio change on the ADS trading price on Nasdaq is expected to take place at the open of trading on March 7, 2022. ADS holders of record on the effective date will not be required to take any action in connection with the ADS ratio change. The exchange of every five then-held ADSs for one new ADS will occur automatically with the then-held ADSs being cancelled and new ADSs being issued by the depositary bank, in each case as of the effective date for the ADS ratio change. The ADSs will continue to be traded on Nasdaq under the symbol "QK." No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements will be distributed to the applicable ADS holders by the depositary bank. As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than five times the ADS price before the change.

06:44 EST Torex Gold Resources reports updated Media Luna resources estimate - Torex Gold Resources announces an updated Mineral Resource estimate for the Media Luna project, which now consists of a gold equivalent Indicated Resource of 4.39 million ounces at an average grade of 5.38 grams per tonne. This reflects a 24% increase in contained AuEq metal in the Indicated Resource category compared to the April 30, 20212 resource estimate of 3.54 Moz AuEq at a grade of 5.27 g/t. Of the current Indicated Resource, 60% of the gold equivalent estimate is attributable to gold, 33% to copper and the remainder to silver . The updated Inferred Resource is estimated at 0.78 Moz AuEq at an average grade of 4.05 g/t AuEq. The resource estimate for Media Luna excludes EPO, a nearby deposit which hosted an Inferred Resource of 1.02 Moz AuEq at a grade of 3.97 g/t as of April 30, 20213. Jody Kuzenko, President and CEO of Torex Gold, stated: "In line with our strategy to continue to invest in growing our reserves and resources, we had another successful infill drill program at Media Luna in 2021, resulting in more than a 0.85 million gold equivalent ounce increase in the Indicated mineral resource category at similar grades as outlined in the April 2021 resource estimate. The conversion rate from the Inferred category to the Indicated category was solid, with Indicated mineral resources increasing by 4.5 million tonnes and Inferred resources declining by 4.9 million tonnes. With $19 million in exploration budgeted for Media Luna in 2022, we expect infill drilling to upgrade additional resources to the Measured and Indicated categories at Media Luna and upgrade Inferred resources at EPO to the Indicated category. Step-out drilling around Media Luna is targeted to expand the overall resource endowment south of the Balsas River. In addition, 80 holes from the 2021 program, which were completed after the cut-off date for the current resource estimate, will be included in the next Mineral Resource update. Overall, we believe the cash flow and return potential outlined in the upcoming Technical Report, which remains on schedule to be released by the end of March 2022, will continue to be enhanced through ongoing exploration success both north and south of the Balsas River. Advancing the development of EPO as a stand-alone deposit could support incremental throughput from Media Luna, enhancing production by pushing out the processing of lower grade stockpiled material."

06:42 EST Toronto-Dominion to acquire First Horizon for $25.00 per share, sees accretion - TD Bank Group (TD) and First Horizon (FHN) announced that they have signed a definitive agreement for TD to acquire First Horizon in an all-cash transaction valued at $13.4B, or $25.00 for each common share of First Horizon. TD accelerates its long-term growth strategy in the United States by acquiring a premier regional bank with an aligned culture and risk-management framework. Following the closing of the transaction, Bryan Jordan, president and CEO of First Horizon, will join TD as vice chair, TD Bank Group, reporting to Bharat Masrani and will join the TD senior executive team. He will also be named to the boards of directors of TD's U.S. banking entities as a director and chair. Jordan will continue to be based in Memphis. On a pro forma basis excluding merger adjustments, TD's U.S. franchise will be a top 6 U.S. bank, with approximately $614B in assets and a network of 1,560 stores, serving over 10.7M U.S. customers across 22 states; globally, TD Bank Group will have approximately C$1.84B in assets, with over 2,600 branches serving the needs of more than 27.5M customers. The transaction is expected to be immediately accretive at closing to TD's adjusted EPS and over 10% accretive to 2023E adjusted EPS on a fully-synergized basis. The transaction is expected to result in a fully-synergized return on invested capital of 10% in 2023. The purchase price represents a 9.8 times multiple of First Horizon's 2023E fully-synergized earnings4 and a 2.1 times multiple to First Horizon's estimated tangible book value at close. TD expects to achieve approximately $610M in pre-tax cost synergies equal to 33% of First Horizon's 2023E non-interest expense6 through a combination of technology and systems consolidation, and other operational efficiencies. TD expects to incur total merger and integration costs of $1.3B primarily in the first two years following close. The transaction is expected to close in Q1 of TD's 2023 fiscal year, and is subject to customary closing conditions, including approvals from First Horizon's shareholders and U.S. and Canadian regulatory authorities. If the transaction does not close prior to November 27, First Horizon shareholders will receive, at closing, an additional 65c per share on an annualized basis for the period from November 27 through the day immediately prior to the closing. The transaction will terminate, unless otherwise extended, if it does not close by February 27, 2023. TD expects to use excess capital on its balance sheet for the transaction, reflecting its capital and liquidity position. Concurrent with this announcement, TD separately announced that the automatic share purchase plan established for its normal course issuer bid will automatically terminate in accordance with its terms. At close, TD's Common Equity Tier 1 ratio is expected to be above 11%. Based on First Horizon's December 31, 2021 balance sheet, the acquisition would add approximately $55B of loans and $75B of deposits to TD's balance sheet, and TD would expect to take a credit mark at close of $880M, or 161 basis points of loans. In addition, TD has agreed to invest $494M in non-voting First Horizon preferred stock to support First Horizon's growth and franchise enhancement, including employee retention programs.

06:41 EST Armada Hoffler announces corporate government enhancements - Armada Hoffler Properties announced that its Board of Directors unanimously approved and adopted an amendment to the Company's Bylaws to reduce the requirements necessary for stockholders to submit binding proposals to amend the Company's Bylaws. In particular, the amendment to the Company's Bylaws reduces the ownership thresholds required for stockholders to submit proposed amendments to the Company's Bylaws to align with the ownership requirements of Rule 14a-8 under Securities Exchange Act of 1934, as amended. Specifically, as a result of the Board's actions, stockholders may propose binding amendments to the Company's Bylaws if they have continuously held: at least $2,000 in market value of the Company's securities entitled to vote on the proposal for at least three years; or at least $15,000 in market value of the Company's securities entitled to vote on the proposal for at least two years; or at least $25,000 in market value of the Company's securities entitled to vote on the proposal for at least one year; or otherwise as provided in Rule 14a-8.

06:39 EST Crinetics, Sanwa enter exclusive licensing agreement for paltusotine - Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho announced that the parties have entered into a strategic partnership to exclusively develop and commercialize paltusotine in Japan. Paltusotine is Crinetics' investigational, orally available nonpeptide somatostatin receptor type 2 agonist being evaluated as a treatment for acromegaly and neuroendocrine tumors, including NETs complicated by carcinoid syndrome. Under the terms of this agreement, Crinetics will receive $13.0 million upfront and will be eligible to receive milestone payments related to the achievement of certain development, regulatory and commercial goals. In addition, upon market approval of paltusotine in Japan, Crinetics will be eligible to receive tiered royalties based on net product sales. Sanwa will have an exclusive right to develop and commercialize the product in Japan and will be responsible for leading the development and commercialization of paltusotine for acromegaly and NETs in Japan. Also, Sanwa will assume all costs associated with clinical trials and regulatory applications associated with these processes. Crinetics retains all rights to develop and commercialize paltusotine outside Japan.

06:26 EST Dentsply Sirona increases quarterly dividend to 12.5c per share - On February 23, 2022, Dentsply Sirona's Board of Directors approved a double-digit increase in the Company's quarterly dividend rate, from the previous rate of $0.11 per share of common stock to $0.125 per share. The dividend is payable on April 8, 2022 to holders of record as of March 25, 2022.

06:22 EST Praxis Precision Medicines expects cash to fund operations into 2Q23 - As of December 31, 2021, Praxis had $275.9 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020. This decrease of $20.7 million primarily reflects cash used in operations of $124.6 million during the year ended December 31, 2021, partially offset by $105.7 million in net proceeds from the follow-on public offering of shares of the Company's common stock in May 2021 and at-the-market offerings during the fourth quarter of 2021. The company's cash, cash equivalents and marketable securities as of December 31, 2021 are expected to fund operations into the second quarter of 2023.

06:17 EST Mersana Therapeutics expects cash to be sufficient into 2H23 - The Company believes its current cash and cash equivalents plus available borrowing under its line of credit will be sufficient to fund its current operating plan commitments into the second half of 2023. As of December 31, 2021, the Company had cash and cash equivalents of $177.9 million and subsequently received a $40 million upfront payment under the Janssen collaboration agreement and $45.6 million of net proceeds from sales of the Company's common stock under its ATM. In addition, the Company currently has the option to borrow $35 million under the new line of credit with Oxford & SVB.

06:15 EST KBR awarded contract to support Shell Global hydrogen liquefaction development - KBR announced it has been awarded a contract to provide professional services to Shell Global Solutions International B.V. for hydrogen liquefaction development. KBR will provide technical solutions as part of concept studies to advance technology for large scale hydrogen liquefaction - an alternative method for long distance renewable energy transport. Liquid Hydrogen also provides a versatile energy solution for a wide variety of end uses including mobility, power generation, industrial and domestic heat, as well as molecular end use markets.

06:14 EST Viatris announces $1B share repurchase program - Viatris announced that its board of directors has authorized a share repurchase program of up to $1B.

06:13 EST Viatris to contribute biosimilars portfolio to Biocon Biologics for $3.34B - The company also announced that following the completion of a strategic review, it has taken the first step in its long-term strategy by reaching a definitive agreement with Biocon Biologics to contribute its biosimilars portfolio to Biocon Biologics, which will become a vertically integrated company. Upon closing, the transaction is expected to provide Viatris with immediate, enhanced financial flexibility, and accelerate its Phase I financial commitments. Viatris intends to continue to invest in expanding its commercial and scientific capabilities in key focus areas for the future, while continuing to participate in the global biosimilars market through its ownership position in Biocon Biologics. Under the terms of the agreement, Viatris will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities, amounting to 2022 estimated revenue of approximately $875M and 2022 estimated adjusted EBITDA of approximately $200M, in exchange for pre-tax consideration of up to $3.34B, which represents a transaction multiple of 16.5x of estimated 2022 biosimilars adjusted EBITDA. At the time of close, which is currently expected to occur in the second half of 2022 subject to satisfaction of closing conditions, including certain regulatory approvals, Viatris will receive $3B in consideration in the form of a $2B cash payment and $1B of convertible preferred equity. The company will also receive up to $335M as additional cash payments that are expected to be paid in 2024. Viatris will own a stake of at least 12.9% of Biocon Biologics, on a fully diluted basis. Viatris will also have certain priority rights with respect to certain liquidity events. Pursuant to the transaction documents, Biocon Biologics will target an initial public offering, or IPO, in India as early as late 2023. Viatris also has the right to designate one member of the Biocon Biologics Board and intends to appoint its president, Rajiv Malik, to this seat. The companies will also enter into a transition services agreement, or TSA, pursuant to which Viatris will provide certain transition services for an expected two-year period, including commercialization services.

06:12 EST Genesis Energy announces 2021 tax packages available online - Genesis Energy announced that the 2021 tax packages, including Schedule K-1s, are now available online. They may be accessed through the K-1 Partner Relations support website www.PartnerDataLink.com/Genesis or through the Quick Link on the Home page at www.genesisenergy.com. The partnership expects to complete mailing of the 2021 Genesis Energy, L.P. tax packages by Monday, March 7, 2022. For additional information, unitholders may call K-1 Partner DataLink toll free at 855-502-0936.

06:10 EST Freyr Battery reports Q4 EPS (24c), consensus (32c) - "We are very pleased with the continued progress we made during the fourth quarter to deliver on our aspiration to become a global, giga scale producer of clean, next-generation batteries," said Tom Jensen, the CEO of FREYR. "With our first two conditional customer offtake agreements signed, our team is focused on reaching a Final Investment Decision on combined Gigafactories 1 & 2, growing our customer backlog, raising capital to fund our expansion, achieving our operational milestones, and enhancing our supply chains to deliver decarbonized cell production globally."

06:05 EST Welbilt expects to deliver improved margins in 2022 - "We are pleased with our fourth quarter results in light of ongoing supply chain disruptions and inflationary pressure on materials and logistics costs," said Bill Johnson. "The drivers of our fourth quarter sales growth were very similar to those of the third quarter. In the Americas, sales to strategic QSRs and fast casual operators increased over last year with improved demand for replacement equipment and stronger rollout activity by large chains across many of our brands. General market sales and KitchenCare aftermarket sales increased in the Americas. Both EMEA and APAC also saw year-over-year growth from strategic QSRs, general market dealers and KitchenCare aftermarket customers. With positive trends for incoming orders and historically high backlogs, we expect sales growth to remain strong for the next several quarters." "The combination of continued aggressive discretionary cost management, improved absorption of fixed costs due to higher volumes, improved net pricing and benefits from Transformation Program, allowed us to deliver an Adjusted Operating EBITDA margin of 18.2 percent in the fourth quarter. With the tools we developed as part of our recently-completed Transformation Program, we will focus on continually improving productivity in our plants and working on other initiatives to help offset production disruptions, parts shortages and inflation from our supply chain. This continued operational improvement, along with realizing benefits from both recent and upcoming price increases, is expected to deliver improved margins in 2022," concluded Johnson.

06:03 EST Aurinia expects cash to fund current plans for at least next few years - The Company believes that it has sufficient financial resources to fund its current plans, which include funding commercial activities, including FDA related post approval commitments, manufacturing and packaging of commercial drug supply, funding its supporting commercial infrastructure, conducting planned research and development programs, investing in its pipeline, executing on its business development strategy and funding its operating activities for at least the next few years.

05:35 EST International Game subsidiary to sell proximity payment business for EUR 700M - International Game announced that its wholly owned subsidiary IGT Lottery S.p.A. has signed a definitive agreement to sell its Italian proximity payment business to PostePay S.p.A. - Patrimonio Destinato IMEL for EUR 700M. Under the agreement, IGT will be selling LIS Holding S.p.A. and indirectly LISPAY S.p.A. These two wholly owned subsidiaries conduct IGT's proximity payment business, which has been the leader in the Italian proximity payments market, offering services through a fully owned advanced payment technology platform and a network of 54,000 points of sale. Services offered range from payments services including bill payments and prepaid payment cards to commercial services providing telco and e-vouchers top up and technological solutions including merchant and enterprise services. The sale price represents an enterprise value of EUR 630M and approximately EUR 70M of net unrestricted cash. The business being sold generated about EUR 228M in gross revenues and approximately EUR 40M in EBITDA in 2021, reflecting a valuation multiple in line with the most recent Italian transactions in the proximity payments sector. IGT will use net proceeds from the transaction primarily to reduce debt. The IGT Board of Directors has approved the transaction, which remains subject to customary closing conditions, including regulatory approvals. Closing of the transaction is expected to occur during the third quarter of 2022.

05:28 EST Orphazyme announces Anders Vadsholt to take over as CEO - Orphazyme announced that CFO Anders Vadsholt will be appointed CEO of Orphazyme effective as of March 1 and thereby replacing Christophe Bourdon as announced in a company announcement on January 31.

05:23 EST Daqo New Energy sees FY22 polysilicon production 120,000MT-125,000MT - The company said, "The Company expects to produce approximately 31,000MT to 32,000MT of polysilicon during the first quarter of 2022. The Company expects to produce approximately 120,000MT to 125,000MT of polysilicon for the full year of 2022, inclusive of the impact of the Company's annual facility maintenance."

05:14 EST Fisker debuts Fisker Ocean all-electric SUV at Mobile World Congress - Fisker debuted its Fisker Ocean all-electric SUV to the European market at Mobile World Congress in Barcelona. The five-passenger Fisker Ocean Sport features a range of 440 KM with a starting price of $37,499 in the U.S. and EUR 41.900 in Spain. The top trim Fisker Ocean Extreme travels 390 miles on a single charge with dual-motor AWD, three driving modes, and a host of first-to-market safety features.

05:08 EST Mullen Automotive provides update on solid-state polymer battery technology - Mullen Automotive announced an update on Mullen's next-generation solid-state polymer battery technology, which is an advancement over the current lithium-Ion batteries. Mullen's testing of solid-state polymer cells reveals the potential for a 150-kilowatt-hour battery pack that delivers over 600-plus miles of range and highlights an 18-minute DC fast charge which can yield over 300 miles of range. Mullen is working towards utilizing solid-state polymer battery packs in its second generation Mullen FIVE EV Crossovers, with in-vehicle prototype testing set for 2025. Mullen's first-generation FIVE EV Crossover, due in late 2024, is planned to launch with traditional lithium-ion cell chemistry. Mullen is also conducting research and development into other advanced battery technologies, including lithium-sulfur and lithium-iron-phosphate. Mullen's ultimate goal is to deliver EV batteries that will surpass the existing lithium-Ion technology.